

2011/2012 Michigan Drug Formulary



Your Extended Family.

Table of Contents

I. Preface

Using the Molina Healthcare of Michigan Drug Formulary.....	pp 4
Specialty Bio-Pharmaceutical Medications.....	pp 5
Antineoplastics and Immunosuppressants	pp 6
State of Michigan, Carve Out.....	pp 7
Prior Authorization Helpful Hints	pp 8
Generic Medications.....	pp 9
Non-Covered Medications	pp 10
Pre-Authorization Request Procedure.....	pp 10
Prescription Quantities	pp 10
Telephone Prescriptions	pp 11
Individual Prescriptions	pp 11
Member After Hours Pharmacy Services	pp 11

II. Therapeutic Categories

Chapter 1. ANTIINFECTIVES	pp 12–15
Chapter 2. ENDOCRINE MEDICATIONS	pp 15–18
Chapter 3. CARDIOVASCULAR MEDICATIONS..	pp 19–23
Chapter 4. RESPIRATORY MEDICATIONS.....	pp 23–27
Chapter 5. GASTROINTESTINAL MEDICATIONS	pp 27–29
Chapter 6. GENITOURINARY	pp 29–30
Chapter 7. CENTRAL NERVOUS SYSTEM.....	pp 30–31
Chapter 8. ANALGESICS.....	pp 31–33
Chapter 9. NEURO-MUSCULAR.....	pp 34
Chapter 10. VITAMINS/ELECTROLYTES	pp 34–35
Chapter 11. HEMATOLOGICAL AGENTS.....	pp 35–36
Chapter 12. OPHTHALMIC MEDICATIONS.....	pp 36–38
Chapter 13. EAR, NOSE AND THROAT MEDICATIONS	pp 38–39
Chapter 14. DERMATOLOGICALS.....	pp 39–41
Chapter 15. MISCELLANEOUS.....	pp 42

III. Clinical Guidelines (MQIC)

Asthma (General Principles).....	pp 43
Asthma (Children 0-4 Years).....	pp 44
Asthma (Children 5-11 Years).....	pp 45
Asthma (Youth 12 and Older and Adults)	pp 46
Management of Diabetes Mellitus.....	pp 47
Outpatient Management of Uncomplicated Deep Venous Thrombosis.....	pp 48
Heart Failure	pp 49
Hypercholesterolemia.....	pp 50
Medical Management of Adults with Hypertension	pp 51
Chronic Kidney Disease	pp 52
Tobacco Control.....	pp 53
Obesity in Adults	pp 54
Childhood Overweight (Treatment)	pp 55
Childhood Overweight (Prevention).....	pp 56
Medical Management of Adults with Osteoarthritis.....	pp 57
Low Back Pain.....	pp 58
Management and Prevention of Osteoporosis.....	pp 59
Acute Pharyngitis in Children.....	pp 60
Acute Bronchitis.....	pp 61

IV. Index

Generic / BRAND Index.....	pp 62–76
----------------------------	----------

MOLINA HEALTHCARE DRUG FORMULARY

The Molina Healthcare of Michigan Drug Formulary was created to help manage the quality of our members' pharmacy benefit. The Formulary is the cornerstone for a progressive program of managed care pharmacotherapy. Prescription drug therapy is an integral component of your patient's comprehensive treatment program. The Formulary was created to ensure Molina members receive high quality, cost-effective, rational drug therapy.

The Molina Healthcare of Michigan Pharmacy and Therapeutics Committee meets quarterly to review and recommend medications for formulary consideration. This assures that the Formulary remains responsive to physician and patient needs. The Committee is composed of providers and pharmacists representing various medical specialties. With a primary consideration to provide a safe, effective and comprehensive Formulary, the Committee evaluated all therapeutic categories and has selected the most cost-effective agent(s) in each class. The Committee also uses reference materials from our Pharmacy Benefits Manager's Pharmacy and Therapeutics Advisory Panel. In addition, the Molina Pharmacy and Therapeutics Committee reviews prior authorization procedures to ensure medications are used safely, following manufacturer's guidelines and current medical practices.

If you are interested in serving on the Pharmacy and Therapeutics Committee, please contact the Pharmacy Department by calling (888) 898-7969, option 1, 5.

Please familiarize yourself with the Drug Formulary as you prescribe medications for Molina Healthcare of Michigan members. Thank you for your cooperation.

PREFACE

USING THE MOLINA HEALTHCARE OF MICHIGAN DRUG FORMULARY

The Molina Healthcare of Michigan Drug Formulary is a listing of preferred drug products eligible for reimbursement by Molina Healthcare of Michigan. All medications are listed by generic name. The medications are organized by therapeutic classes. For your convenience a table of contents by therapeutic category is found at the beginning and an index which lists formulary drugs by their brand and generic names is listed at the end of the Drug Formulary Book.

Specialty Bio-Pharmaceutical Medications

Caremark Pharmacy

In November 2003 Molina Healthcare of Michigan (MHM) entered into an exclusive contractual arrangement with *Caremark Specialty Pharmacy* to be the provider of specialty bio-pharmaceutical medications. This program allows our health plan to obtain the best possible price and at the same time, obtain other services to assist in the overall healthcare management of the member. *Caremark* medications may be delivered directly to the patient or to your office.

NOTE: *Caremark Specialty Pharmacy* will need the patient's telephone number to verify certain information such as continued insurance eligibility and availability to sign for the package. Please see below for a list of some of the preferred medications handled by *Caremark Specialty Pharmacy*. **Other medications are non-formulary.**

If you have any questions, please feel free to call Pharmacy Services at (888) 898-7969. The pharmacy fax line is (888) 373-3059.

ACTIMMUNE	GLEEVEC	NEXAVAR	SANDOSTATIN
ADVATE	HELIXATE	NOVANTRONE	SPRYCEL
ALPHANATE	HERCEPTIN	NOVOSEVEN	STIMATE
ALPHANINE	HUMATE P	OCETREOTIDE	SUTENT
APLIGRAF	HUMATROPE	PEGASYS**	SYNAGIS
ARIXTRA	HUMIRA	PEG-INTRON**	SYNAREL
ARANESP	INCRELEX	PROCRIT	TEMODAR
AUTOPLEX	INFERGEN	PROFILNINE	TEVTROPIN**
AVONEX	INTRON A	PROPLEX	THALOMID
BEBULIN	KOATE	PULMOZYME	THROMATE
BENEFIX	KOGENATE	RAPTIVA	THYROGEN
COPAXONE	LEUKINE	REBETOL	TOBI
COPEGUS	LOVENOX	REBETRON	TRACLEER
DDAVP	LUCENTIS	RECOMBINATE	TYKERB
ELAPRASE	LUPRON	REFACTO	TRELSTAR
ENBREL	MONARCH M	REMODULIN	VIDAZA
EPOGEN	MONCLATE	REVATIO	VANTAS
EXTAVIA**	MONONINE	REVLIMID	VISUDYNE
EUFLEXXA	MYOBLOC	RHOGAM	WHINRHO
FEIBA-VH	NEUMEGA	RIBAVIRIN	XELODA
FORTEO	NEULASTA	REFERON	XOLAIR
FRAGMIN	NEUPOGEN	SAIZEN	ZOLADEX

** Formulary Preferred

All medications on this list require a Prior Authorization be faxed to Molina Healthcare of Michigan.

Antineoplastics and Immunosuppressants

All FDA-Approved, Non-injectable Antineoplastics and immunosuppressants are eligible for coverage. Injectable and certain high cost oral medications in this class are subject to Prior Authorization and must be filled through *Caremark Specialty Pharmacy*.

Generic Name	Brand Name
Melphalan	ALKERAN
Anastrozole	ARIMIDEX
Bicalutamide	CASODEX
Lomustine	CEENU
Mycophenolate Mofetil	CELLCEPT
Cyclophosphamide	CYTOXAN
Estramustine	EMCYT
Levamisole	ERGAMISOL
Flutamide	EULEXIN
Toremifine	FARESTON
Letrozole	FEMARA
Altrefamine	HEXALEN
Hydroxyurea	HYDREA
Azathioprine	IMURAN
Chlorambucil	LEUKERAN
Mitotane	LYSODREN
Procarbazine	MATULANE
Megestrol	MEGACE
Busulfan	MYLERAN
Tamoxifen	NOLVADEX
Tacrolimus	PROGRAF
Mercaptoprine	PURINETHOL
Sirolimus	RAPAMUNE
Methotrexate	RHEUMATREX
Cyclosporine	SANDIMUNNE
Cyclosporine	NEORAL
Testolactone	TESLAC
Thioguanine	THIOGUANINE
Etoposide	VEPESID
Pipobroman	VERCYTE
Tretinoin	VESANOID

Other medications are added in this class regularly. Please contact MHM for coverage information if the medication you are requesting does not appear on this list at (888) 898-7969.

State of Michigan, Carve Out

Effective October 2004, the State of Michigan enacted a Carve out for all Psychotropic and HIV/AIDS related medications. Effective April 2010, additional classes of medication have been added to the Carve Out. These classes include ADHD, Anti-Depressive, Sedative, Anti-Anxiety and Anti-Convulsant medications. Claims for these medications must be submitted directly to the State of Michigan, First Health. Molina members may be responsible for a \$1.00-\$3.00 co-pay on these medications as indicated by State rules.

Effective 10/1/2004	STELAZINE	DIASTAT, ACUDIAL	PHENOBARBITAL
ABILIFY	SUBOXONE	DILANTIN	PHENYTEK
AGENERASE	SUSTIVA	DORAL	PRISTIQ
AKINETON	SYMBYAX	EDLUAR	PROSOM
APTIVUS	THORAZINE	EFFEXOR, XR	PROVIGIL
ARTANE	TRILAFON	ELAVIL	PROZAC, WEEKLY
ATRIPLA	TRIZIVIR	EMSAM	REMERON
CAMPREL	TRUVADA	FELBATOL	RESTORIL
CLOZARIL	VIDEX, -EC	FOCALIN, XR	RITALIN, SR, LA
COGENTIN	VIRACEPT	GABITRIL	ROZEREM
COMBIVIR	VIRAMUNE	HALCION	SARAFEM
CRIVAN	VIREAD	INTUNIV	SECONAL SODIUM
EMTRIVA	ZERIT	KEPPRA, XR	SERAX
EPIVIR	ZIAGEN	KLONOPIN	SERZONE
EPZICOM	ZYPREXA, ZYDIS	LAMICTAL, ODT, XR	SINEQUAN
FAZACLO	Effective 4/1/2010	LEXAPRO	SOMNOTE, NOCTEC
FORTOVASE	ADDERALL, XR	LIBRIUM	SONATA
FUZEON	AMBIEN CR	LIMBITROL, DS	STAVZOR
GEODON	ANAFRANIL	LUDIOMIL	STRATTERA
HALDOL	APLENZIN, ER	LUMINAL	SURMONTIL
HIVID	ASENDIN	LUNESTA	TEGRETOL, XR
INAPSINE	ATIVAN	LUVOX, CR	TOFRANIL, PM
INVIRASE	BANZEL	LYRICA	TOPAMAX
KALETRA	BUSPAR, VANSAPAR	MARPLAN	TRANXENE T-TAB
KEMADRIN	BUTISOL SODIUM	MEBARAL	TRIAVIL, ETRAFON
LEXIVA	CARBATROL	METADATE ER, CD	TRILEPTAL
LOXITANE	CELEXA	MILTOWN	VALIUM
MELLARIL	CELONTIN	MYSOLINE	VIMPAT
MOBAN	CEREBYX	NARDIL	VIVACTIL
NAVANE	CONCERTA	NEURONTIN	VYVANSE
NORVIR	CYMBALTA	NIRAVAM	WELLBUTRIN, SR, XL
ORAP	DALMANE	NORPRAMIN	XANAX, -XR
PROLIXIN	DAYTRANA	NUVIGIL	ZARONTIN
RESCRIPTOR	DEPAKENE	PAMELOR	ZOLOFT
RETROVIR	DEPAKOTE, ER	PARNATE	ZONEGRAN
REYATAZ	DESYREL	PAXIL, CR	
RISPERDAL	DEXEDRINE	PEGANONE	
SEROQUEL	DEXTROSTAT	PEXEVA	

PRIOR AUTHORIZATION HELPFUL HINTS

To ensure the quickest response possible from MHM Pharmacy Department please provide the following information with the Prior Authorization request.

Class of Medication/Diagnosis	Requested Clinical Information
Cholesterol Lowering	Lipid Panel
Diabetics	A1c Report
Osteoperosis	Bone Density Study
Proton Pump Inhibitor (For BID dosing only)	Endoscopy Report
Onychomycosis	Culture and Sensitivity Report
Pain Management	Medication Log, Narcotic Contract and Progress Notes
Non-Formulary Medications	Medication Log and/or Progress Notes documenting previous use of formulary medications
Non-Preferred Medications for new Members	Medication Log and/or Progress Notes documenting previous use of requested medications

GENERIC MEDICATIONS

Selected medications have FDA-approved generic equivalents available. The Molina Healthcare of Michigan drug endorsement states...”generic drugs will be dispensed whenever available”.

If the use of a particular brand-name becomes medically necessary as determined by the provider, the provider must submit a Prior Authorization request and explain clinically why the branded drug product is medically necessary.

Molina Healthcare of Michigan encourages the use of quality generic products. Only those generic products which have received an “A” rating by the FDA should be utilized. Physicians are encouraged to write “Brand Only” or “DAW” only when medically necessary. Members are not permitted to ask for brand name drugs.

The Pharmacy and Therapeutics Committee recognizes that certain medications possess narrow therapeutic dose response characteristics. Therefore, the following drugs are not required to be generically substituted, unless the patient has been therapeutically maintained on the generic product for a period of time.

Generic Name	Brand Name
Digoxin	Lanoxin, Digitek
Levothyroxine	Synthroid or Levoxyl
Cyclosporine	Sandimmune, Neoral
Warfarin	Coumadin

NON-COVERED MEDICATIONS

Please note that certain medications are not covered. These include, but are not limited to:

- Medications for Cosmetic Purposes, including Retinoic Acid
- Experimental or Investigational Medications
- Convenience Dosage Forms (Transdermal Patches), not listed in the Formulary
- Fertility Drugs – Per MDCH Contract
- Erectile Dysfunction Drugs
- OTC Medications not found in formulary
- Medications used for non-FDA approved indications, unless approved by Medical Director
- Oxycontin
- Nutritional Supplements/Medical Foods (May be available through Utilization Management Department)

PRIOR AUTHORIZATION REQUEST PROCEDURE

Prescriptions for medications requiring prior approval or for medications not included on the Molina Drug Formulary may be approved when medically necessary and when formulary alternatives have demonstrated ineffectiveness. When these exceptional situations arise, the physician may fax a completed drug prior authorization form to Molina at (888) 373-3059. The forms may be obtained from Molina Healthcare of Michigan Pharmacy Prior Authorization Department by calling (888) 898-7969 and selecting 1 as a Provider and 5 for the Pharmacy Department or by visiting <http://www.molinahealthcare.com/medicaid/providers/mi/forms>. Trials of pharmaceutical samples do not guarantee or override prior authorization approval.

PRESCRIPTION QUANTITIES

Prescriptions should be written for a therapeutic supply of medications (the amount to appropriately treat a medical condition) up to a maximum of a 30-day supply. Trial quantities may be used when trying new treatments, if appropriate. Some drugs may have quantity limits.

TELEPHONE PRESCRIPTIONS

Whenever possible, the patient should be given the prescription in writing or delivered directly to the pharmacy via e-prescribing. This will allow the patient to make use of the most convenient network pharmacy and enable the pharmacy to fill the prescription after normal office hours.

INDIVIDUAL PRESCRIPTIONS

Each prescription must legally be prescribed for one individual only. If prescribing for a family, each family member must receive a prescription.

MEMBER AFTER HOURS PHARMACY SERVICES

POLICY - After normal business hours, which is defined as after the close of Molina Healthcare of Michigan Pharmacy Department (Mon-Fri) 8:00 AM-6:00 PM EST.

Molina specialized agents are available at the CVS/Caremark Help Desk and may be contacted for assistance at (800) 791-6856. The after hours pharmacy policy goes into effect as described in the Procedure section.

PURPOSE - This policy establishes the infrastructure and procedures for plan members to obtain medications on an emergency basis and on a 24-hour/day/7day/week basis.

SCOPE - This policy applies to CVS/Caremark contracted pharmacy providers dispensing medications to Molina Healthcare of Michigan members after the Plan's normal business hours.

PROCEDURE

During after hours situations contact the CVS/Caremark Helpdesk at (800) 791-6856 for an override to approve a three day supply of any medication which "when not given may cause the member's condition to worsen".

MOLINA HEALTHCARE OF MICHIGAN DRUG FORMULARY

Generic Available*	Generic Name	Brand Name
--------------------	--------------	------------

Chapter 1 ANTIINFECTIVES

1.1 Penicillins

- ANTIBIOTICS IN SUSPENSION FORM DO NOT REQUIRE A PA FOR MEMBERS 12 YEARS AND YOUNGER
- Bronchitis due to viral infections should not be treated with antibiotics.
- Use with caution in patients with a reported allergy to cephalosporins and in patients with renal impairment.
- Despite increasing antibiotic resistance, Amoxicillin continues to remain the drug of choice for otitis media in children. Amoxicillin doses of 60-90mg/kg/day (in divided doses) may be needed for suspect/proven PCN-resistant S. pneumoniae.
- The secondary choice for patients with contraindications to amoxicillin is SMZ/ TMP (generic Bactrim, Septra).

First Line:

*	Dicloxacillin	DYNAPEN
*	Ampicillin	PRINCIPEN
*	Amoxicillin	TRIMOX
*	Penicillin VK	VEETIDS

2nd Line:

*	Amoxicillin/potassium clavulanate	AUGMENTIN (Max#20)
---	-----------------------------------	--------------------

1.2 Cephalosporins

- Dosage may need to be modified in patients with renal impairment. Inappropriately large doses may cause seizures.
- Use with caution in patients with a reported sensitivity or allergy to penicillin due to cross-sensitivity in about 10% of patients.

First Line:

*	Cefaclor	CECLOR
*	Cephalexin	KEFLEX

2nd Line:

*	Cefuroxime	CEFTIN
*	Cefadroxil Monohydrate	DURICEF

PRIOR AUTHORIZATION REQUIRED

*	Cefaclor	CECLOR CD [^]
*	Cefprozil	CEFZIL [^]
*	Cefdinir	OMNICEF [^]
	Cefixime	SUPRAX [^]

[^]SUSPENSION FORM - NO PA MEMBERS 12 & UNDER

MOLINA HEALTHCARE OF MICHIGAN DRUG FORMULARY

Generic Available*	Generic Name	Brand Name
1.3 Erythromycins		
<ul style="list-style-type: none"> Erythromycin is the most cost-effective alternative to penicillin for the treatment of many infections in penicillin-allergic patients. Co-administration may increase levels of theophylline, carbamazepine (Tegretol), cyclosporin (Sandimmune, Neoral, Sangcya) and warfarin (Coumadin). 		
First Line:		
*	Erythromycin ethylsuccinate	EES
*	Erythromycin base, (enteric-coated)	ERY-TAB
*	Erythromycin stearate	ERYTHROCIN
2nd Line:		
*	Azithromycin	ZITHROMAX (250 mg Max #6 & 500 mg Max #3)

PRIOR AUTHORIZATION REQUIRED

*	Clarithromycin	BIAXIN+^
*	Telithromycin	KETEK
*	Azithromycin	ZITHROMAX 1GM POWDER PACK**

^SUSPENSION FORM - NO PA MEMBERS 12 & UNDER

**NO PA REQUIRED WHEN BILLED AS A 1 DAY STAT DOSE

+ Up to #28 available for treatment of H. Pylori if billed same day as Amoxicillin

1.4 Tetracyclines

- Contraindicated for children less than 8 years old, or pregnant and nursing mothers.
- Absorption is decreased by dairy products, iron, bismuth and antacids. Doxycycline is minorly affected.

*	Tetracycline	SUMYCIN
*	Doxycycline	VIBRAMYCIN (Caps only)

1.5 Quinolones

- Not generally considered First Line therapy for most infections.
- Consider use for:
 - Sensitive staphylococcal infections when another effective, less expensive oral antibiotic is not an option.
 - Gram negative, soft tissue, bone, renal and wound infections when the only other option is parenteral antibiotics.
 - Respiratory infections in cystic fibrosis patients as an alternative to parenteral antibiotics.
- Co-administration with theophylline may increase serum theophylline levels. Co-administration with warfarin (Coumadin) may increase Coumadin's effects.

MOLINA HEALTHCARE OF MICHIGAN DRUG FORMULARY

Generic Available*	Generic Name	Brand Name
<ul style="list-style-type: none"> • Common side effects for ciprofloxacin (Cipro) are restlessness and vomiting. 		
*	Ciprofloxacin	CIPRO (Max #20)
PRIOR AUTHORIZATION REQUIRED		
*	Moxifloxacin	AVELOX
*	Ofloxacin	FLOXIN
*	Levofloxacin	LEVAQUIN
<u>1.6 Aminoglycosides</u>		
*	Neomycin	
<u>1.7 Sulfonamides</u>		
*	Smz/tmp	BACTRIM, SEPTRA
*	Sulfisoxazole	GANTRISIN
*	Sulfisoxazole/ erythromycin Susp.	PEDIAZOLE
<u>1.8 Antituberculosis</u>		
*	Isoniazid	ISONIAZID
*	Ethambutol	MYAMBUTOL
*	Pyrazinamide	PYRAZINAMIDE
*	Rifampin	RIFADIN
*	Pyridoxine	VITAMIN B-6
<u>1.9 Antifungal</u>		
First Line:		
*	Fluconazole	DIFLUCAN 100 mg or 200 mg (Max #21)
*	Griseofulvin	FULVICIN UE, FULVICIN PG
*	Clotrimazole	MYCELEX (troches only)
2nd Line:		
*	Terbinafine tablets	LAMISIL TABLETS (Max #30)
PRIOR AUTHORIZATION REQUIRED		
*	Ketoconazole	NIZORAL
*	Posaconazole	NOXAFIL
<u>1.10 Antiviral</u>		
*	Amantadine	SYMMETREL
*	Acyclovir	ZOVIRAX (tab, capsules, Ointment Max 30 gram/60 days, Cream Max 2 gram/60 days)

MOLINA HEALTHCARE OF MICHIGAN DRUG FORMULARY

Generic Available*	Generic Name	Brand Name
<u>1.11 Antimalarial</u>		
	Pyrimethamine Primaquine Phosphate	DARAPRIM PRIMAQUINE
<u>1.12 Anthelmintics</u>		
*	Mebendazole	VERMOX
<u>1.13 Miscellaneous Antiinfectives</u>		
*	Clindamycin	CLEOCIN (150mg only)
*	Metronidazole Nitrofurantoin monohyd/ macrocrystals LA	FLAGYL MACROBID
*	Nitrofurantoin	MACRODANTIN
*	Trimethoprim	TRIMPEX

PRIOR AUTHORIZATION REQUIRED

Nitazoxanide	ALINIA
Entecavir	BARACLUDGE

Chapter 2

ENDOCRINE MEDICATIONS

2.1 Systemic Corticosteroids

2.1.1 Glucocorticosteroids

*	Hydrocortisone	CORTEF
*	Dexamethasone	DECADRON
*	Methylprednisolone	MEDROL
*	Prednisolone	ORAPRED (syrup- No PA for members 18 and under)
*	Prednisone	ORASONE
*	Prednisolone Prednisolone Syrup	PREDNISOLONE PRELONE

2.1.2 Mineralocorticoids

*	Fludrocortisone	FLORINEF
---	-----------------	----------

2.2 Estrogens

*	Estradiol Estrogens, conjugated	ESTRACE PREMARIN (tabs, vaginal cream)
---	------------------------------------	--

MOLINA HEALTHCARE OF MICHIGAN DRUG FORMULARY

Generic Available*	Generic Name	Brand Name
PRIOR AUTHORIZATION REQUIRED		
*	Estradiol Transdermal	ESTRADERM PATCH, VIVELLE
2.2.1	Estrogen/Progesterone Combination	FEMHRT PREMPHASE PREMPRO
<u>2.3 Oral Contraceptives #28 covered per 28 days</u>		
2.3.1 Mono-Phasic Oral Contraceptives		
*	Levonorgestrel/ethinyl estradiol	ALESSE
*	Levonorgestrel/ethinyl estradiol	LEVLEN
*	Norgestrel/ethinyl estradiol	LO OVRAL, OVRAL
*	Ethinyl estradiol/ norethindrone acetate	LOESTRIN
*	Ethinyl estradiol/norethindrone	MODICON
*	Levonorgestrel/ethinyl estradiol	NORDETTE
*	Ethinyl estradiol/desogestrel	ORTHO-CEPT
*	Ethinyl estradiol/norgestimate	ORTHO-CYCLEN
*	Norethindrone/ethinyl estradiol	ORTHO-NOVUM 1/35
*	Norethindrone/mestranol	ORTHO-NOVUM 1/50
*	Norethindrone/ethinyl estradiol	OVCON-35, OVCON-50
*	Ethinyl estradiol/Drosirenone	YASMIN
2.3.2	Bi-Phasic Oral Contraceptives	
*	Norethindrone/ethinyl estradiol	ORTHO-NOVUM 10/11
2.3.3	Tri-Phasic Oral Contraceptives	
*	Norethindrone/ethinyl estradiol	ESTROSTEP
*	Norethindrone/ethinyl estradiol	ORTHO-NOVUM 7/7/7
*	Norgestimate/ethinyl estradiol	ORTHO TRI-CYCLEN
*	Levonorgestrel/ethinyl estradiol	TRIPHASIL
2.3.4	Progestin Only Oral Contraceptives	
*	Norethindrone	MICRONOR
*	Norgestrel	OVRETTE
<u>2.4 Miscellaneous Contraceptives</u>		
*	Medroxyprogesterone acetate	DEPO-PROVERA (150mg/ml)
<u>2.4A Other Contraceptives</u>		
	Etonogestrel/ethinyl estradiol	NUVA RING
<u>2.5 Progestins</u>		
*	Norethindrone acetate	AYGESTIN
*	Medroxyprogesterone	PROVERA, CYCRIN

MOLINA HEALTHCARE OF MICHIGAN DRUG FORMULARY

Generic Available*	Generic Name	Brand Name
<u>2.6 Oral Hypoglycemics</u>		
	Pioglitazone/Metformin	ACTOPLUS (Step Therapy: Three month trial of Metformin and A1c < 8.5)
	Pioglitazone	ACTOS (Step Therapy: Three month trial of Metformin and A1c < 8.5)
*	Glimepiride	AMARYL
*	Glyburide	DIABETA
*	Chlorpropamide	DIABINESE
*	Metformin	GLUCOPHAGE
*	Metformin, Extended-Release	GLUCOPHAGE XR
*	Glipizide	GLUCOTROL
*	Glipizide extended release	GLUCOTROL XL
*	Metformin/Glipizide	GLUCOVANCE
*	Glyburide	GLYNASE
	Sitagliptin/Metformin	JANUMET (Step Therapy: Three month trial of Metformin and A1c < 8.5)
	Sitagliptin	JANUVIA (Step Therapy: Three month trial of Metformin and A1c < 8.5)
	Saxagliptin/Metformin	KOMBIGLYZE XR (Step Therapy: Three month trial of Metformin and A1c < 8.5)
	Saxagliptin	ONGLYZA (Step Therapy: Three month trial of Metformin and A1c < 8.5)
*	Tolbutamide	ORINASE
*	Tolazamide	TOLINASE
PRIOR AUTHORIZATION REQUIRED		
*	Acarbose	PRECOSE

2.7 Insulins/Supplies

- Insulin PENS are covered for all members under 16 years of age
- Insulin PEN Step Therapy for members over 16 years of age: Covered for patients with documented retinopathy and neuropathy
- #200 test strips are covered for insulin dependent & pregnant members (filling prenatal vitamins)
- #50 test strips are covered for all other members

Insulin Lispro	HUMALOG, NOVOLOG
Insulin-Human, recombin	HUMULIN, NOVOLIN
Insulin Glargine	LANTUS
Glucometer	TRUE TRACK/ TRUE RESULT
Glucose Test Strips	TRUE TRACK/ TRUE TEST
Insulin Syringes, OTC Lancets, OTC	

MOLINA HEALTHCARE OF MICHIGAN DRUG FORMULARY

Generic Available*	Generic Name	Brand Name
<u>2.8 Glucagon</u>		
	Glucagon	GLUCAGON KIT
<u>2.9 Antithyroid Drugs</u>		
*	Propylthiouracil	PTU
*	Methimazole	TAPAZOLE
<u>2.10 Thyroid Hormones</u>		
*	Thyroid desiccated	ARMOUR THYROID
	Levothyroxine	SYNTHROID, LEVOXYL
<u>2.11 Endometriosis Therapy</u>		
*	Danazol	DANOCRINE
	Nafarelin	SYNAREL
<u>2.12 Osteoporosis Drugs</u>		
*	Alendronate	FOSAMAX
PRIOR AUTHORIZATION REQUIRED		
*	Raloxifene	EVISTA^
	Calcitonin Salmon	MIACALCIN NASAL SPRAY^
^NO PA REQUIRED FOR MEMBERS OVER 50 YEARS OF AGE. TO EXPEDITE RESPONSE PLEASE SUBMIT CURRENT BONE DENSITY STUDY		
<ul style="list-style-type: none"> • Management of osteoporosis should start with: <ul style="list-style-type: none"> • Adequate dietary calcium, including calcium supplementation in therapeutic doses. • Weight bearing exercise. • Estrogen replacement, if not contraindicated. • Reduction of caffeine intake. • Bisphosphonate patients should be carefully selected to ensure that they are able to be compliant with dosing/absorption requirements. • Fosamax 5mg is the only strength indicated for prevention, rather than treatment of osteoporosis. • Evista is not considered first-line therapy for a majority of patients. Its use should be reserved for those patients unable to tolerate estrogen or HRT therapy, due to intolerable adverse effects or those at a very high risk of breast cancer. Long term effects of Evista are not known at this time. 		
<u>2.13 Other Endocrine Drugs</u>		
*	Ergocalciferol	CALCIFEROL
*	Bromocriptine	PARLODEL

MOLINA HEALTHCARE OF MICHIGAN DRUG FORMULARY

Generic Available*

Generic Name

Brand Name

Chapter 3

CARDIOVASCULAR MEDICATIONS

3.1 Cardiac Glycosides

- Digitalis toxicity is increased by hypokalemia.
- Co-administration of digoxin with verapamil or quinidine increases digoxin levels and may cause toxicity.

	Digoxin Solution	DIGOXIN SOLUTION (No PA for members 12 and under)
--	------------------	--

*	Digoxin	DIGITEK, LANOXIN
---	---------	------------------

3.2 Nitrates

- Tolerance to oral nitrates such as isosorbide dinitrate (Isordil) may result in an increase in the dose required. Oral nitrates should be prescribed no more frequently than TID with a nitrate-free period of 10-12 hours per day.

	Isosorbide dinitrate SR	DILATRATE SR
*	Isosorbide mononitrate	IMDUR, MONOKET, ISMO
*	Isosorbide dinitrate	ISORDIL (excluding Tembids)
*	Nitroglycerin SR	NITRO-BID
*	Nitroglycerin patch	NITRO-DUR, DEPONIT
*	Nitroglycerin spray	NITROLINGUAL SPRAY
*	Nitroglycerin Oint	NITROL OINT
*	Nitroglycerin	NITROSTAT

NOTE: IN THE TREATMENT OF HYPERTENSION, JNC VII GUIDELINES CONTINUE TO RECOMMEND DIURETICS OR BETA-BLOCKERS TO BE FIRST LINE, COST EFFECTIVE THERAPY, EXCEPT IN AFRICAN AMERICANS.

3.3 Metabolic Modulators

PRIOR AUTHORIZATION REQUIRED

Ranolazine

RANEXA

3.4 Beta-Blockers

3.4.1 Beta-1 Specific

*	Carvedilol	COREG
*	Metoprolol	LOPRESSOR
*	Atenolol/Chlorthalidone	TENORETIC

MOLINA HEALTHCARE OF MICHIGAN DRUG FORMULARY

Generic Available*	Generic Name	Brand Name
	Atenolol	TENORMIN
	Metoprolol ER	TOPROL XL
3.4.2 Non-Selective		
	Nadolol	CORGARD
	Propranolol	INDERAL
	Propranolol ER	INNOPRAN XL
	Penbutolol	LEVATOL
	Labetalol	NORMODYNE
	Bisoprolol	ZEBETA
3.4.3 Beta-Blocker Combinations		
	Bisoprolol/HCTZ	ZIAC
<u>3.5 Calcium Antagonists</u>		
	Nifedipine SR	ADALAT-CC
	Verapamil	CALAN
	Verapamil SR	CALAN SR
	Diltiazem & Diltiazem ER	DILACOR XR, TIAZAC, CARDIZEM, -CD, -SR
	Isradipine	DYNACIRC, DYNACIRC CR
	Amlodipine	NORVASC
	Nifedipine	PROCARDIA

3.6 Antidysrhythmic Drugs

- Avoid combining agents of the same class or agents with potentially additive side effects (QT interval prolongation, negative inotropic effects, etc.) Antiarrhythmics may provoke arrhythmia (proarrhythmia); hypokalemia enhances the proarrhythmic effect of many drugs.
- The risk of proarrhythmia increases with worsening left ventricular function and ischemia.

*	Amiodarone	CORDARONE, PACERON
*	Procainamide SR	PROCANBID
*	Procainamide	PRONESTYL
*	Quinidine gluconate	QUINAGLUTE
*	Quinidine sulfate SR	QUINIDEX
*	Quinidine Sulfate	QUINIDINE SULFATE
	Dronedarone	MULTAQ (Step Therapy: Three month trial of Amiodarone)

3.7 Angiotensin Converting Enzyme Inhibitor

- ACE inhibitors may precipitate acute renal failure and hyperkalemia in patients with severe heart failure, pre-existing renal disease, or hypovolemic states.

MOLINA HEALTHCARE OF MICHIGAN DRUG FORMULARY

Generic Available*	Generic Name	Brand Name
		<ul style="list-style-type: none"> • Use of ACE inhibitors in the second and third trimesters of pregnancy can harm or even kill a developing fetus and are contraindicated in pregnancy. • Co-administration of ACE inhibitors with potassium or potassium-sparing diuretics increases the risk of hyperkalemia.
*	Quinapril	ACCUPRIL
*	Captopril	CAPOTEN
*	Benazepril	LOTENSIN
*	Trandolapril	MAVIK
*	Lisinopril	ZESTRIL
3.7.1	Angiotensin Converting Enzyme Inhibitor/Diuretic Combinations	
*	Quinapril/HCTZ	ACCURETIC
*	Captopril/HCTZ	CAPOZIDE
*	Benazepril/HCTZ	LOTENSIN - HCT
*	Lisinopril/HCTZ	ZESTORETIC
3.7.2	Angiotensin Converting Enzyme Inhibitor/Calcium Channel Blocker Combinations	
	Trandolapril/Verapamil ER	TARKA
3.7.2	Angiotensin Converting Enzyme Inhibitor/Diuretic Combinations	
*	Enalapril	VASOTEC
3.7.2	Angiotensin Converting Enzyme Inhibitor/Calcium Channel Blocker Combinations	
*	Enalapril/HCTZ	VASORETIC
3.7.3	Angiotensin II Receptor Antagonists	
	<ul style="list-style-type: none"> • ARBs may be useful in those patients who require treatment with an ACE, but are unable to tolerate common ACE adverse effects, such as cough. 	
	Olmesartan	BENICAR (Step Therapy: Three month trial of COZAAR)
*	Losartan	COZAAR (Step Therapy: Three month trial of ACE Inhibitor)
3.7.4	Angiotensin II Antagonist Combination	
	Olmesartan/HCTZ	BENICAR HCT (Step Therapy: Three month trial of ACE Inhibitor)
*	Losartan/HCTZ	HYZAAR (Step Therapy: Three month trial of ACE Inhibitor)

MOLINA HEALTHCARE OF MICHIGAN DRUG FORMULARY

Generic Available*	Generic Name	Brand Name
<u>3.8 Antiadrenergic Agents-Centrally Acting</u>		
*	Methyldopa	ALDOMET
*	Clonidine	CATAPRES (tablets only)
*	Doxazosin	CARDURA
<u>3.9 Alpha Blockers</u>		
*	Terazosin	HYTRIN
*	Prazosin	MINIPRESS
<u>3.10 Vasodilators</u>		
*	Hydralazine	APRESOLINE
<u>3.11 Diuretics</u>		
3.11.1 Loop Diuretics		
*	Bumetanide	BUMEX
*	Furosemide	LASIX
*	Furosemide Solution	LASIX SOLUTION (No PA for members 12 and under)
3.11.2 Thiazide & Related Diuretics		
*	Hydrochlorothiazide	HYDRODIURIL
*	Indapamide	LOZOL
*	Metolazone	ZAROXOLYN
3.11.3 Potassium Sparing Diuretics		
*	Spironolactone/HCTZ	ALDACTAZIDE
*	Spironolactone	ALDACTONE
*	Triamterene/HCTZ	DYAZIDE
*	Triamterene/HCTZ	MAXZIDE
3.11.4 Carbonic Anhydrase Inhibitor		
*	Acetazolamide	DIAMOX
*	Methazolamide	NEPTAZANE
<u>3.12 Cholesterol Lowering Agents</u>		
<ul style="list-style-type: none"> • Drug treatment for lowering cholesterol should be considered only when patients have not responded to non-drug therapies such as dietary restrictions, smoking cessation and exercise programs. Patients who are unwilling to be compliant with lifestyle modifications may not be appropriate candidates for drug therapy. • The selection of a cholesterol-lowering drug should be based upon a) patient risk factors for coronary artery disease and b) the percentage decrease in levels that is required. Treatment criteria are based on nationally recognized treatment guidelines. 		

MOLINA HEALTHCARE OF MICHIGAN DRUG FORMULARY

Generic Available*	Generic Name	Brand Name
3.12.1 HMG CoA Reductase	Rosuvastatin	CRESTOR (Step Therapy: Three month trial of Simvastatin)
*	Pravastatin	PRAVACHOL (10, 20, 40 mg)
*	Simvastatin	ZOCOR (10, 20, 40 mg)

PRIOR AUTHORIZATION REQUIRED

Ezetimibe/Simvastatin VYTORIN

TO EXPEDITE RESPONSE PLEASE INCLUDE CURRENT LIPID PANEL ALONG WITH REQUEST FORM

3.12.2 Other Cholesterol Lowering Agents

- Niacin has several side effects including flushing, itchy skin, GI distress, liver toxicity, hyperglycemia and hyperuricemia. To avoid flushing, give niacin with meals and start with a low dose, titrating up slowly. One aspirin or ibuprofen given 1 hour before the niacin dose helps against persistent flushing.

*	Colestipol	COLESTID TABLETS
*	Fenofibrate	LOFIBRA
*	Gemfibrozil	LOPID
*	Niacin, Niacin SR	NIACIN, SLO-NIACIN, NIASPAN
*	Cholestyramine	QUESTRAN (can only)
*	Cholestyramine	QUESTRAN LIGHT (can only)

3.13 Miscellaneous Cardiovascular Drugs

*	Pentoxifylline	TRENTAL
---	----------------	---------

Chapter 4

RESPIRATORY MEDICATIONS

4.1 Antihistamines

- Nasonex not covered without documented trial and failure of Flonase.
- Use of OTC, first generation antihistamines is recommended as initial therapy. Antihistamines should be used with caution in patients taking MAO inhibitors, alcohol or other CNS depressants.

4.1.1 Single-Entity Products

Consider OTC PRODUCTS as first line therapy

*	Fluticasone	FLONASE
*	Azelastine	ASTEPRO
*	Hydroxyzine	ATARAX, VISTARIL
*	Diphenhydramine	BENADRYL OTC BENADRYL (syrup)

MOLINA HEALTHCARE OF MICHIGAN DRUG FORMULARY

Generic Available*	Generic Name	Brand Name
*	Chlorpheniramine	CHLOR-TRIMETON OTC
	Cromolyn-Nasal inhaler	NASALCROM OTC
*	Cyproheptadine	PERIACTIN
*	Clemastine	TAVIST

Lower Sedating Antihistamines

- The use of lower sedating antihistamines is usually reserved for those patients who engage in high risk activities that would be compromised from a preferred antihistamine.

*	Loratadine	CLARITIN OTC
*	Loratadine	CLARITIN SYRUP OTC (No PA for members 18 and under)
	Loratadine/pseudoeph	CLARITIN-D OTC
*	Cetirizine	ZYRTEC OTC
*	Ceririzine	ZYRTEC SYRUP OTC (No PA for members 6 and under)
*	Cetirizine/Pseudoephedrine	ZYRTEC-D OTC

PRIOR AUTHORIZATION REQUIRED

*	Fexofenadine	ALLEGRA
*	Fexofenadine/Pseudoephedrine	ALLEGRA-D

4.1.2 Combination Products

OTC Products May Be Used As First Line Therapy

*	Triprolidine/ Pseudoephedrine, OTC	ACTIFED OTC (tabs)
	Brompheniramine/ Pseudoephedrine	BROMFED, -PD
*	Chlortrimeton/Decong.	CONTAC OTC (12 hour caps)
	Chlorpheniramine/ Pseudoephedrine	DECONAMINE SR
*	Bromphen/Decong	DIMETAPP OTC (tabs)
*	Carbinoxamine/phenylephrine	CERON (tabs)

4.2 Decongestant Products

*	Pseudoephedrine, OTC	SUDAFED OTC (tabs)
---	----------------------	--------------------

4.3 Antitussives & Expectorants

*	Hydrocodone/Phenyl/CTM	HISTUSSIN HC
---	------------------------	--------------

MOLINA HEALTHCARE OF MICHIGAN DRUG FORMULARY

Generic Available*	Generic Name	Brand Name
*	Guaifenesin/ Dextromethorphan	HUMIBID DM, FENESIN DM
*	Guaifenesin	HUMIBID LA
*	Phenylephrine/promethazine	PHENERGAN VC
*	Dextromethorphan/ promethazine	PHENERGAN DM
*	Codeine/promethazine	PHENERGAN/ CODEINE
*	Codeine/phenylephrine/ promethazine	PHENERGAN VC & COD
*	Guaifenesin, OTC	ROBITUSSIN OTC
*	Guaifenesin/Codeine	ROBITUSSIN AC
*	Guaifenesin/ Pseudoephedrine/ Codeine	ROBITUSSIN DAC
*	Guaifenesin/ Dextromethorphan	ROBITUSSIN DM OTC
*	Benzonatate	TESSALON PERLES
*	Guaifenesin/ Dextromethorphan	TUSSI-ORGANIDIN- DM NR
*	Guaifenesin/Codeine	TUSSI-ORGANIDIN NR

4.4 Antiasthmatics

4.4.1 Adrenergic Stimulants-Inhalers

*	Albuterol	PROAIR HFA INHALER
---	-----------	-----------------------

PRIOR AUTHORIZATION REQUIRED

Fomoterol	FORADIL [^]
Salmeterol	SEREVENT [^]
Pirbuterol	MAXAIR AUTOINHALER

[^] NO PA REQUIRED AFTER MEDICATION HAS BEEN
FILLED CONSISTENTLY FOR THREE MONTHS

4.4.2 Adrenergic Stimulants-Solutions

*	Metaproterenol	ALUPENT
*	Albuterol	PROVENTIL

4.4.3 Adrenergic Stimulants-Oral Tabs

*	Terbutaline	BRETHINE
*	Albuterol	PROVENTIL

MOLINA HEALTHCARE OF MICHIGAN DRUG FORMULARY

Generic Available*	Generic Name	Brand Name
4.4.4 Xanthine Derivatives		
<ul style="list-style-type: none"> Theophylline levels may be decreased by cigarette smoking. There are a significant number of drug interactions with theophylline and commonly prescribed medicines such as phenytoin, isoniazid, beta-blockers, oral contraceptives and erythromycin. 		
*	Theophyllines, 8-12 hour	SLO-BID GYROCAPS
*	Theophyllines, 8-24 hour	THEO-DUR
*	Theophyllines	UNIPHYL
4.4.5 Cortico-steroids For Inhalation		
<ul style="list-style-type: none"> Inhaled corticosteroids are useful for chronic maintenance treatment and prevention of asthma/COPD symptoms. They should be considered as first-line therapy for patients with moderate to severe, chronic symptoms of asthma. Inhaled corticosteroids are not effective for PRN treatment of acute symptoms. Use of short-acting inhaled beta-2 agonists more than 2 times a week may indicate the need to initiate long-term control therapy. ONLY ONE INHALED CORTICOSTERIOD COVERED PER MONTH 		
*	Beclomethasone	QVAR
	Budesonide	PULMICORT RESPULES (No PA for members 9 and under)
	Budesonide	PULMICORT FLEXHALER (Step Therapy: Two month trial of QVAR)
	Mometasone	ASMANEX (Step Therapy: Two month trial of QVAR)
	Mometasone/Formoterol	DULERA (Step Therapy: Two month trial of ICS)

PRIOR AUTHORIZATION REQUIRED

Fluticasone/Salmeterol	ADVAIR
Budesonide/Formoterol	SYMBICORT

4.4.6 Leukotriene Inhibitors

- These products are not indicated for acute attacks, but are used to help prevent asthma symptoms.
- They may be less effective than inhaled corticosteroids.
- Exercise great caution when reducing doses of corticosteroids in patients taking Singulair. Aggressive corticosteroid reduction could lead to Churg-Strauss syndrome, which can cause neurological, pulmonary, or cardiac complications.

PRIOR AUTHORIZATION REQUIRED

Zafirlukast	ACCOLATE
Montelukast	SINGULAIR^

^NO PA REQUIRED FOR CHEW TAB FOR MEMBERS 9 YEARS OF AGE AND UNDER

MOLINA HEALTHCARE OF MICHIGAN DRUG FORMULARY

Generic Available*	Generic Name	Brand Name
4.4.7 Other Drugs For Asthma/Respiratory Use		
	Inhaler enhancement device	AEROCHAMBER, & MASK, EASIVENT, MICROCHAMBER
*	Ipratropium	ATROVENT INHALER SOLUTION
	Sodium Chloride solution-canister	BRONCHO SALINE
*	Ipratropium/Albuterol	COMBIVENT
	Cromolyn	CROMOLYN NEBULIZER SOLUTION
	Tiotropium Bromide	SPIRIVA
<ul style="list-style-type: none"> • Spacers consistently increase the delivery of inhaled medications in all age groups, regardless of technique and are strongly recommended. 		

Chapter 5

GASTROINTESTINAL MEDICATIONS

- Recommended lifestyle changes to include: Smoking cessation, weight loss, elevating head of bed, avoidance of spicy foods, late night snacks and alcoholic beverages.
- Antacids are effective in treating many gastrointestinal problems, including duodenal ulcer. They are as effective as H2 blockers in non-ulcer dyspepsia and should be considered initially.
- Non prescription strength famotidine (PEPCID AC) is effective for dyspepsia and is also a cost-effective alternative to other drugs.
- Initial therapy of duodenal ulcer may include H2 blockers, sucralfate or antacids for 8 weeks. Maintenance H2 therapy should be considered for patients with recurrence or bleeding complications.

5.1 Antidiarrheal Preparations

- Pepto Bismol should be avoided in children because it contains salicylate. Administration of salicylic acid derivatives (ASA) to children, including teenagers, with acute febrile illness has been associated with the development of Reye's syndrome.
- | | | |
|---|------------------------|------------------------------|
| * | Loperamide HCl | IMODIUM OTC |
| * | Diphenoxylate/atropine | LOMOTIL |
| * | Attapulgite | PARAPECTOLIN, KAOPECTATE OTC |
| * | Bismuth Subsalicylate | PEPTO BISMOL OTC |

MOLINA HEALTHCARE OF MICHIGAN DRUG FORMULARY

Generic Available*	Generic Name	Brand Name
5.2 Ulcer Therapy		
5.2.1 H2 Antagonists		
	• Caution should be used in co-administration of cimetidine with warfarin, theophylline, phenytoin, benzodiazepines and other drugs.	
*	Famotidine	PEPCID AC OTC (20mg)
*	Cimetidine	TAGAMET
*	Ranitidine	ZANTAC (syrup, tabs)
5.2.2 Proton-pump inhibitors		
*	Omeprazole caps	OMEPRAZOLE (20mg)
PRIOR AUTHORIZATION REQUIRED		
*	Lansoprazole	PREVACID OTC + (No PA for members 12 and under)
*	Pantoprazole	PROTONIX
TO EXPEDITE RESPONSE FOR TWICE DAILY DOSING REQUESTS PLEASE INCLUDE MOST RECENT ENDOSCOPY REPORT		
+ Up to #56 OTC available for treatment of H. Pylori if billed same day as Amoxicillin		
5.2.3 Other anti-ulcer products, antacids		
*	Sucralfate	CARAFATE
*	Misoprostol	CYTOTEC
*	Antacid Liquid	MAALOX/MAALOX TC OTC
*	Antacid Liquid	MYLANTA/II OTC
*	Simethicone	MYLICON OTC
*	Sodium Bicarbonate	SODIUM BICARBONATE (Max #60)
*	Calcium carbonate	TUMS OTC
5.2.4 H. Pylori treatments		
	• H. Pylori has been shown to be the cause of a large percentage of duodenal ulcers. Treatment of H. pylori, when present, greatly reduces ulcer recurrence rates.	
	Ranitidine bismuth citrate	TRITEC
5.3 Antiemetic		
*	Meclizine	ANTIVERT
*	Prochlorperazine	COMPazine
*	Promethazine	PHENERGAN
*	Trimethobenzamide	TIGAN
*	Ondansetron	ZOFRAN (Max #12 tabs)

MOLINA HEALTHCARE OF MICHIGAN DRUG FORMULARY

Generic Available*	Generic Name	Brand Name
<u>5.4 Digestants/Stool Softeners/Laxative</u>		
*	Lactulose	CEPHULAC
*	Docusate sodium	COLACE OTC
*	Lipase/protease/amylase	CREON
*	Bisacodyl	DULCOLAX (limit 2 months)
*	Docusate/casanthrol	PERI-COLACE OTC
*	Psyllium powder	METAMUCIL POWDER
*	Polyethylene Glycol	MIRALAX POWDER
<u>5.5 Antispasmodics & Drugs Affecting GI Motility</u>		
*	Dicyclomine	BENTYL
*	PEG Solution	COLYTE, COLYTE FLAVORED
*	Belladonna alkaloids/ phenobarbital	DONNATAL
*	Hyoscyamine sulfate	LEVSIN, LEVSINEX
*	CDZ/Clidinium	LIBRAX
*	Metoclopramide	REGLAN
	Lubiprostone	AMITIZA (Step Therapy: MIRALAX, LACTULOSE and COLACE trial)
<u>5.6 Sulfonamide/Mesalamine Products</u>		
*	Mesalamine	ASACOL
	Sulfasalazine	AZULFIDINE
	Mesalamine	APRISO (Step Therapy: 3 months Asacol)

<h3 style="margin: 0;">Chapter 6</h3> <h2 style="margin: 0;">GENITOURINARY</h2>

6.1 Vaginal Antiinfectives

OTC Products may be used as First Line Therapy

*	Acetic Acid/Oxquin	ACI-JEL
*	Clindamycin	CLEOCIN (vag cream)
*	Fluconazole Tablet	DIFLUCAN 150mg tab (Max #2)
*	Miconazole	MONISTAT

MOLINA HEALTHCARE OF MICHIGAN DRUG FORMULARY

Generic Available*	Generic Name	Brand Name
*	Clotrimazole	MYCELEX-G, GYNE-LOTTRIMIN
*	Nystatin	MYCOSTATIN
*	Triple sulfa vag cream	SULTRIN (vag cream)
*	Metronidazole	VANDAZOLE

6.2 Miscellaneous Vaginal

Amino Acid/Urea Cervical Cream	AMINO-CERV
-----------------------------------	------------

6.3 Anticholinergic-Antispasmodics

*	Oxybutynin	DITROPAN
*	Oxybutynin XL	DITROPAN XL (Step Therapy: Three months of Ditropan)

PRIOR AUTHORIZATION REQUIRED

*	Tolterodine Tartrate ER Propanthelene	DETROL LA PRO-BANTHINE
---	--	---------------------------

6.4 Cholinergic Drugs

*	Bethanechol	URECHOLINE
---	-------------	------------

6.5 Urinary Analgesics

*	Phenazopyridine	PYRIDIUM
---	-----------------	----------

6.6 Miscellaneous Genitourinary

*	Terazosin	HYTRIN
*	Doxazosin	CARDURA

PRIOR AUTHORIZATION REQUIRED

Alfuzosin	UROXATROL
-----------	-----------

Chapter 7

CENTRAL NERVOUS SYSTEM

7.1 Dementia

Donepezil	ARICEPT
-----------	---------

PRIOR AUTHORIZATION REQUIRED

Rivastigmine	EXELON
Galatamine	RAZADYNE
Memantine	NAMENDA

MOLINA HEALTHCARE OF MICHIGAN DRUG FORMULARY

Generic Available*	Generic Name	Brand Name
*	Nicotine transdermal	NICOTROL PATCH (limit 3 months)
*	Nicotine polacrilex	NICORETTE GUM (Max #60 pieces, limit 3 months)
*	Bupropion SR	ZYBAN (limit 3 months)

PRIOR AUTHORIZATION REQUIRED

Varenicline	CHANTIX
Nicotine Inhaler	NICOTROL INHALER
Nicotine Nasal Spray	NICOTROL SPRAY

QUANTITY LIMITS MAY APPLY

Chapter 8 ANALGESICS

8.1 Non-Narcotic Analgesics

*	Aspirin-Tabs,	ASPIRIN OTC
*	Aspirin- enteric coated Tabs	ASPIRIN OTC
*	Salsalate	DISALCID, MONOGESIC
*	Butalbital/APAP/Caffeine	FIORICET
*	Butalbital/APAP/Caffeine/ Codeine	FIORICET w/CODEINE
*	Butalbital/ASA/Caffeine	FIORINAL
*	Butalbital/ASA/Caffeine/ Codeine	FIORINAL w/CODEINE
*	Acetaminophen	TYLENOL OTC
*	Tramadol HCL	ULTRAM

8.2 Narcotic Analgesics

- These drugs all have abuse potential. Tolerance and dependence can occur with prolonged use.
- Prescriptions should not exceed recommended doses of acetaminophen, aspirin or codeine. Patients on full doses of these medications should be warned not to supplement their pain relief with OTC drugs to avoid toxic levels.
- Combining these agents with alcohol, muscle relaxants or antihistamines can cause excessive sedation and confusion.
- Patients should be cautioned not to use machinery or to do other things that could be dangerous if they become drowsy or dizzy.

*	Aspirin/Codeine	ASPIRIN, CODEINE
*	Hydromorphone	DILAUDID
*	Hydrocodone/Acetaminophen	LORCET

MOLINA HEALTHCARE OF MICHIGAN DRUG FORMULARY

Generic Available*	Generic Name	Brand Name
*	Hydrocodone Bitartrate/APAP	LORTAB (elixir only)
*	Methadone	METHADONE
*	Morphine sulfate CR	MS CONTIN (Max #90/30 days)
*	Morphine sulfate IR	MSIR (Max #90/30 days)
*	Hydrocodone/Acetaminophen	NORCO
*	Oxycodone/APAP	PERCOCET
*	Oxycodone/ASA	PERCODAN
*	Acetaminophen/codeine	TYLENOL w/CODEINE
*	Oxycodone/APAP	TYLOX
*	Hydrocodone/ Acetaminophen	VICODIN, VICODIN ES

PRIOR AUTHORIZATION REQUIRED

Morphine sulfate CR

ORAMORPH SR,
KADIAN

- Use of high-dose, long-acting narcotic analgesics should be under direct supervision of a pain management specialist or oncologist.
- Patients on high-dose, long-acting narcotic analgesics may be candidates for case management.

8.3 Non-Steroidal Anti-Inflammatory Drugs

- All NSAIDs have similar effectiveness and differ very little in their toxicity and side effects. Therefore, generically available NSAIDs should be considered as first line therapy.
- Combinations of two or more NSAIDs offer no advantage, but do increase the chances of drug interaction and toxicity. Patients may be taking OTC NSAIDs without MD awareness.
- Concurrent use of an H2 blocker with an NSAID has not been shown to reduce the incidence of gastric ulceration or bleeding. Misoprostol (Cytotec) may be a better choice for preventing ulcer formation in patients at risk.
- NSAID use in the following conditions deserves special consideration of potential risks: History of GI bleeding or ulcer; chronic anti-coagulation, asthma, aspirin allergy, renal failure, hypertension or congestive heart failure.

*	Naproxen Sodium	ANAPROX. ANAPROX DS
*	Sulindac	CLINORIL
*	Piroxicam	FELDENE
*	Indomethacin	INDOCIN
*	Etodolac	LODINE, -XL
*	Meloxicam	MOBIC
*	Ibuprofen	MOTRIN
*	Naproxen	NAPROSYN
*	Diclofenac	VOLTAREN (tabs only)

MOLINA HEALTHCARE OF MICHIGAN DRUG FORMULARY

Generic Available*	Generic Name	Brand Name
PRIOR AUTHORIZATION REQUIRED		
*	Diclofenac/Misoprostol	ARTHROTEC
*	Oxaprozin	DAYPRO
*	Ketoprofen CR Capsules	ORUVAIL
*	Nabumentone	RELAFEN
*	Ketoralac tromethamine	TORADOL (tabs)

8.4 Antirheumatics

*	Methotrexate	METHOTREXATE
*	Hydroxychloroquine	PLAQUENIL

8.5 Drugs To Prevent And Treat Gout

*	Probenecid	
*	Indomethacin	INDOCIN
*	Allopurinol	ZYLOPRIM

8.6 Migraine

- Patients with 3 or more migraine attacks per month may be appropriate candidates for prophylactic therapy with standard therapy, including beta blockers or tricyclics.
- In patients who do not respond to therapy, consider rebound effect.
- Migraine patients should be monitored for narcotic analgesic overuse or abuse.
- **Only one migraine medication may be filled every 30 days.**

• QUANTITY LIMITS MAY APPLY

*	Ergotamine/caffeine	CAFERGOT
*	APAP/ASA/Caffeine	EXCEDRIN MIGRAINE OTC
*	Sumatriptan	IMITREX (Max #9/45)
*	Isometheptene/ dichloralphenazone/APAP Eletriptan Hydrobromide	MIDRIN RELMAX (Max #6/30, Step Therapy: Imitrex Tabs)
	Zolmitriptan	ZOMIG (Max #6/30, Step Therapy: Imitrex Tabs)

PRIOR AUTHORIZATION REQUIRED

Dihydroergotamine	MIGRANAL NASAL SPRAY
-------------------	-------------------------

MOLINA HEALTHCARE OF MICHIGAN DRUG FORMULARY

Generic Available*	Generic Name	Brand Name
--------------------	--------------	------------

Chapter 9

NEURO-MUSCULAR

9.1 Antiparkinson Drugs

*	Biperiden HCL	AKINETON
*	Selegiline	ELDEPRYL
*	Bromocriptine	PARLODEL
*	Carbidopa/levodopa	SINEMET
*	Amantadine HCL	SYMMETREL

9.2 Skeletal Muscle Relaxants

*	Cyclobenzaprine	FLEXERIL (10mg)
*	Baclofen	LIORESAL
*	Methocarbamol	ROBAXIN
*	Carisoprodol/ASA	SOMA COMPOUND
*	Carisoprodol	SOMA (350mg)
*	Tizanidine	ZANAFLEX

PRIOR AUTHORIZATION REQUIRED

*	Orphenadrine/ASA/Caffeine	NORGESIC, NORGESIC FORTE
---	---------------------------	-----------------------------

9.3 Other

*	Pyridostigmine	MESTINON
---	----------------	----------

Chapter 10

VITAMINS/ELECTROLYTE

10.1 Prenatal Vitamins

*	Chewable Prenatal Vitamin	NATACHEW
*	Prenatal vitamins	NATALINS RX
*	Prenatal vitamins	NIFEREX PN, PN FORTE
*	Prenatal vitamins	PRENATE 90

10.2 Vitamins

*	Vitamin D	DRISDOL (Max #4)
*	Vitamin K	MEPHYTON
*	Multi-Vitamins & fluoride	POLY-VI-FLOR, POLY-VI-SOL (tabs, drops)

MOLINA HEALTHCARE OF MICHIGAN DRUG FORMULARY

Generic Available*	Generic Name	Brand Name
*	Multi-Vitamin w/ fluoride & iron	POLY-VI-FLOR w/ IRON, POLY-VI-SOL w/IRON
*	Calcitrol	ROCALTROL
*	Multi-Vitamin	THERAPEUTIC TAB, CHILDRENS CHEWABLE VITAMIN
*	Multi-Vitamin w/iron	THERA-M, CHILDRENS CHEWABLE VITAMIN w/IRON
*	Multi-Vitamins & fluoride	TRI-VI-FLOR (tabs, drops)
<u>10.3 Other</u>		
*	Levocarnitine	CARNITOR
*	Ferrous Sulfate	FEOSOL OTC (tabs, solution)
*	Ferrous Gluconate	FERGON OTC
*	Sodium Fluoride drops/tabs	LURIDE
*	Calcium Carbonate	OS-CAL, TUMS OTC
*	Ped. Electrolyte Solution	PEDIALYTE OTC
<u>10.4 Potassium Supplements</u>		
*	Potassium Cl Liquid	K-DUR-10, K-DUR 20
*	Potassium Cl tab	KLOTRIX, K-TABS
*	Potassium Cl efferv Tabs	K-LYTE/CL

Chapter 11

HEMATOLOGICAL AGENTS

11.1 Hematopoetic

*	Folic acid	
*	Folic acid/B-12/Iron	NIFEREX-150 FORTE

11.2 Anticoagulant Drugs

*	Warfarin	COUMADIN
	Enoxaparin	LOVENOX

Lovenox treatment lasting longer than 7 days requires PA and must be filled through Caremark Specialty Pharmacy.

MOLINA HEALTHCARE OF MICHIGAN DRUG FORMULARY

Generic Available*	Generic Name	Brand Name
11.3 Antiplatelet Drugs		
	<ul style="list-style-type: none"> Aspirin-OTC remains as the first-line antiplatelet drug. Plavix should be reserved for those patients who are unable to tolerate or are resistant to aspirin therapy. 	
*	Dipyridamole/ASA Aspirin- Tabs, enteric coated tabs Clopidogrel	AGGRENEX ASPIRIN OTC PLAVIX
PRIOR AUTHORIZATION REQUIRED		
*	Ticlopidine	TICLID

Chapter 12

OPHTHALMIC MEDICATION

12.1 Alpha-adrenoreceptor agonists

Brimonidine 0.2%	ALPHAGAN P
------------------	------------

12.2 Anti-Inflammatory Agents

12.2.1 Corticosteroids

*	Dexamethasone 0.1%	DECADRON, AK-DEX SOLN
	Fluorometholone 0.1%	FML, FML FORTE, FML S.O.P
*	Prednisolone 0.12%, 1%	PRED FORTE, PRED MILD

12.2.2 Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)

	Ketorolac	ACULAR
	Ketorolac 0.4%	ACULAR LS
*	Nedrocromil	ALOCRIAL
*	Flurbiprofen	OCUFEN
*	Diclofenac 0.1%	VOLTAREN
*	Ketotifen	ZADITOR OTC

12.3 Anti-Allergic Agents

*	Lodoxamide	ALOMIDE
	Cromolyn sodium 4%	OPTICROM
	Naphazoline/Antazoline	VASOCON-A

PRIOR AUTHORIZATION REQUIRED

*	Olopatadine	PATADAY
*	Olopatadine 0.1%	PATANOL

MOLINA HEALTHCARE OF MICHIGAN DRUG FORMULARY

Generic Available*	Generic Name	Brand Name
<u>12.4 Antimicrobial agents</u>		
12.4.1 Antibiotics and Antibiotic Combinations		
*	Bacitracin	AK-TRACIN
*	Sulfacetamide	BLEPH 10, SODIUM SULAMYD
*	Gentamicin	GENOPTIC
*	Erythromycin	ILOTYCIN OPTH OINT
*	Gramicidin/neomycin/polymyxin B	NEOSPORIN
*	Ofloxacin	OCUFLOX
*	Polymyxin/TMP	POLYTRIM
*	Tobramycin	TOBREX
PRIOR AUTHORIZATION REQUIRED		
	Gatifloxacin	ZYMAR
12.4.2 Antibiotic-Corticosteroid Combinations		
*	Sulfacetamide/prednisolone	BLEPHAMIDE
*	Hydrocortisone/neomycin/polymyxin B	CORTISPORIN
	Prednisolone acetate 0.5%/neomycin/polymyxin B	POLY PRED SUSP
	Prednisolone acetate 1%/gentamicin	PRED-G DROPS
	Prednisolone acetate 0.6%/gentamicin	PRED-G S.O.P. OINT
*	Tobramycin/dexamethsone	TOBRA-DEX
*	Sulfacetamide/Pred	VASOCIDIN
12.4.3 Antifungal		
	Natamycin 5%	NATACYN
12.4.4 Antiviral		
*	Trifluridine 1%	VIROPTIC
<u>12.5 Beta-adrenoreceptor Antagonists</u>		
*	Levobunolol 0.25%, 0.5%	BETAGAN
*	Betaxolol	BETOPTIC 0.25% SUSP, BETOPTIC 0.5% SOLN.
*	Timolol maleate 0.25%, 0.5%	TIMOPTIC SOLUTION
*	Timolol maleate 0.25%, 0.5%	TIMOPTIC-XE GEL
<u>12.6 Carbonic Anhydrase Inhibitors</u>		
*	Dorzolamide HCL 1%	TRUSOPT

MOLINA HEALTHCARE OF MICHIGAN DRUG FORMULARY

Generic Available*	Generic Name	Brand Name
<u>12.7 Dilating Agents</u>		
12.7.1 Anticholinergic		
*	Cyclopentolate	CYCLOGYL
*	Atropine	ISOPTO ATROPINE
*	Homatropine	ISOPTO HOMATROPINE
*	Scopolamine	ISOPTO HYOSCINE
*	Tropicamide	MYDRIACYL
12.7.2 Sympathomimetic		
*	Phenylephrine	NEOSYNEPHRINE
<u>12.8 Miotics</u>		
*	Pilocarpine hydrochloride	PILOCAR
<u>12.9 Prostaglandins</u>		
*	Dorzolamide/Timolol Latanoprost 0.005%	COSOPT XALATAN, TRAVATAN Z (Step Therapy: Two Months of Xalatan)
<u>12.10 Sympathomimetics</u>		
*	Dipivefrin	PROPINE
<u>12.11 Miscellaneous Ophthalmic Products</u>		
*	Polyvinyl Alcohol	ARTIFICIAL TEARS

Chapter 13

EAR, NOSE AND THROAT MEDICATIONS

13.1 OTIC Antiinfectives

*	Chloramphenicol	CHLOROMYCETIN
*	Ciprofloxacin/ Dexamethasone	CIPRODEX
*	Ofloxacin	FLOXIN OTIC

- FLOXIN OTIC is indicated for use in patients with chronic suppurative otitis media with perforated TM, and for acute otitis media with tympanostomy tubes. For patients with common otitis externa, use of cortisporin is recommended.

13.2 OTIC Steroid-Anti-infective Combinations

*	Hydrocortisone/neo/ polymyxin B	CORTISPORIN OTIC
*	Acetic Acid	VOSOL

MOLINA HEALTHCARE OF MICHIGAN DRUG FORMULARY

Generic Available*	Generic Name	Brand Name
<u>13.3 Miscellaneous OTIC Products</u>		
*	Benzocaine/antipyrine	AURALGAN
*	Carbamide peroxide 6.5%	DEBROX OTC
*	Hydrocort./acetic acid	VOSOL HC OTIC
<u>13.4 Throat Medications</u>		
*	Clotrimazole	MYCELEX TROCHE
*	Nystatin suspension	MYCOSTATIN
*	Lidocaine viscous	XYLOCAINE VISCIOUS
<u>13.5 Corticosteroids, Inhaled Nasal</u>		
	• Nasonex not covered without documented trial and failure of Flonase	
*	Fluticasone	FLONASE
PRIOR AUTHORIZATION REQUIRED		
	Mometasone	NASONEX
Chapter 14		
DERMATOLOGICALS		
All topical dosage forms of listed items are formulary items.		
All topical anti-acne medications covered for patients ages 10 to 30 only.		
<u>14.1 Anti-Acne Medications</u>		
*	Clindamycin 1%, topical solution, lotion, gel	CLEOCIN-T
*	Benzoyl peroxide gel, lotion 2.5%, 5%, 10%	DESQUAM-E, DESQUAM-X
*	Erythromycin, topical solution, gel, pads	ERYCETTE
*	Tretinoin	RETIN A (cream only)
<u>14.2 Topical Antiinfectives</u>		
*	Gentamicin	GARAMYCIN
*	Bacitracin ointment	OTC
*	Triple Antibiotic ointment	OTC
*	Polysporin ointment	OTC
*	Silver Sulfadiazine	SILVADENE

MOLINA HEALTHCARE OF MICHIGAN DRUG FORMULARY

Generic Available*	Generic Name	Brand Name
14.3 Topical Anti-Fungals		
*	Clotrimazole-cream/solution	MYCELEX OTC
*	Triamcinolone/nystatin	MYCOLOG II (30gm limit)
*	Nystatin	MYCOSTATIN
*	Ciclopirox	LOPROX
*	Clotrimazole/ betamethasone	LOTRISONE
*	Tolnaftate cream	TINACTIN OTC
14.4 Topical Corticosteroids		
<ul style="list-style-type: none"> • Pediatric patients may have greater susceptibility to topical corticosteroid-induced HPA axis suppression than adults. • Avoid using high potency steroids on the face, neck, groin, or axilla. Occlusive dressings or diapers increase the potency of the steroid. 		
GROUP IV (LOW POTENCY)		
*	Hydrocortisone	HYTONE
*	Desonide	TRIDESILON
GROUP III (MEDIUM POTENCY)		
*	Prednicarbate	DERMATOP
*	Momentasone furoate	ELOCON
*	Triamcinolone acetonide	KENALOG
*	Fluocinolone acetonide	SYNALAR
PRIOR AUTHORIZATION REQUIRED		
*	Desoximetasone	TOPICORT LP
GROUP II (HIGH POTENCY)		
*	Betamethasone dipropionate	DIPROSONE
*	Fluocinonide	LIDEX
*	Hydrocortisone valerate	WESTCORT
PRIOR AUTHORIZATION REQUIRED		
*	Halcinonide	HALOG, HALOG-E
GROUP I (VERY HIGH POTENCY)		
*	Halobetasol	ULTRAVATE
*	Betamethasone valerate	VALISONE

MOLINA HEALTHCARE OF MICHIGAN DRUG FORMULARY

Generic Available*	Generic Name	Brand Name
PRIOR AUTHORIZATION REQUIRED		
*	Augmented betamethasone dipropionate	DIPROLENE
	Diflorasone diacetate	FLORENE, FLORENE E, PSORCON, -E
*	Desoximetasone	TOPICORT

14.5 Topical Corticosteroids in Combination

Hydrocortisone/pramoxine	EPIFOAM
--------------------------	---------

14.6 Topical Non-Steroid Anti-Inflammatory

- PROTOPIC and ELIDEL are not indicated in patients under 2 years of age.

PRIOR AUTHORIZATION REQUIRED		
	Tacrolimus	PROTOPIC
	Pimecrolimus	ELIDEL

14.7 Scabicides/Pediculocides

Treatment of choice is OTC Nix

*	Lindane lotion, shampoo	KWELL
*	Permethrin	NIX-OTC
*	Pyrethins combo.	A-200 OTC
*	Permethrin	ELIMITE

14.8 Anorectal

*	Hydrocortisone Acetate	ANUSOL HC SUPP
*	Hydrocortisone/pramoxine	PROCTOCREAM HC
*	Hydrocortisone	PROCTOCREAM HC 2.5%

14.9 Anti-Psoriatics

*	Anthralin	DRITHOCREME
---	-----------	-------------

PRIOR AUTHORIZATION REQUIRED		
	Cacipotriene	DOVONEX

14.10 Miscellaneous Topicals

*	Calamine Lotion	
*	Mupirocin	BACTROBAN
*	Podofilox	CONDYLOX
*	Aluminum Chloride	DRYSOL
*	Fluoruracil	EFUDEX
*	Lidocaine/Prilocaine	EMLA
*	Nystatin	MYCOSTATIN POWDER

MOLINA HEALTHCARE OF MICHIGAN DRUG FORMULARY

Generic Available*	Generic Name	Brand Name
*	Hexachlorophene Selenium Sulfide	PHISOHEX SELSUN SHAMPOO- RX
*	Lidocaine	XYLOCAINE (cream only)
*	Acyclovir	ZOVIRAX (No PA for members 12 and over)

Chapter 15

MISCELLANEOUS

*	Insect Sting Kit	ANA-GUARD, ANA-KIT
*	Caffeine Citrate	CAFFEINE CITRATE SOLUTION (No PA for members 2 and under)
*	Barium Enema Prep Kit	FLEETS PREP KIT
*	Sodium Polystyrene	KAYEXALATE
*	Methylergonovine	METHERGINE
*	Acetylcysteine	MUCOMYST (5 day supply only)
*	Condoms	OTC various (Max #12)
*	Spermicidal Jelly/foam	OTC various
*	Chlorhexidine Gluconate	PERIDEX
*	Calcium Acetate	PHOSLO
	Diaphragm	VARIOUS

Michigan Quality Improvement Consortium Guideline

General Principles for the Diagnosis and Management of Asthma

The following guideline recommends general principles and key clinical activities for the diagnosis and management of asthma.		Recommendation and Level of Evidence
Eligible Population	Key Components	
<p>Children and adults with the following:</p> <ul style="list-style-type: none"> • Wheezing • History of cough (worse particularly at night), recurrent wheeze, recurrent difficulty in breathing, recurrent chest tightness • Symptoms occur or worsen in the presence of exercise, viral infection, inhalant allergens, irritants, changes in weather, strong emotional expression (laughing or crying hard), stress, menstrual cycles • Symptoms occur or worsen at night, awakening the patient 	<p>Diagnosis and management goals</p>	<ul style="list-style-type: none"> • Detailed medical history and physical exam to determine that symptoms of recurrent episodes of airflow obstruction are present • Use spirometry in all patients ≥ 5 years of age to determine that airway obstruction is at least partially reversible [C]. • Consider alternative causes of airway obstruction. <p>Goals of therapy are to achieve control by [A]:</p> <ul style="list-style-type: none"> • Reducing impairment (prevent chronic symptoms, minimize need for rescue therapy with short-acting beta₂-agonists (SABA), maintain near-normal lung function and activity levels) • Reducing risk (prevent exacerbations, minimize need for emergency care or hospitalization, prevent loss of lung function or prevent reduced lung growth in children, have minimal or no adverse effects of therapy)
	<p>Assessment and monitoring</p>	<ul style="list-style-type: none"> • Assess asthma severity to initiate therapy. (Use severity classification chart, assessing both domains of impairment [B] and risk [C] to determine initial treatment.) • Assess asthma control to monitor and adjust therapy [B]. (Use asthma control chart, assessing both domains of impairment and risk to determine if therapy should be maintained or adjusted. (Step up if necessary; step down if possible.)) • Obtain lung function measures by spirometry at least every 1-2 years [B], more frequently for not well-controlled asthma. • Schedule follow-up care. In general, consider scheduling patients at 2- to 6-week intervals while gaining control [D]; at 1- to 6-month intervals if a step-down in therapy is anticipated [D]. • Assess asthma control, medication technique, written asthma action plan, patient adherence and concerns at every visit.
	<p>Education</p>	<ul style="list-style-type: none"> • Provide self-management education [A]. Teach and reinforce: self-monitoring to assess control and signs of worsening asthma (either symptom or peak flow monitoring) [B], using written asthma action plan (review differences between long-term control and quick-relief medication); taking medication correctly (inhaler technique and use of devices); avoiding environmental and occupational factors that worsen asthma. • Tailor education to literacy level of patient; integrate education into all points of care; appreciate potential role of patient's cultural beliefs and practices in asthma management [C]. • Develop written action plan in partnership with patient [B].
	<p>Control environmental factors and comorbid conditions</p>	<ul style="list-style-type: none"> • Recommend measures to control exposures to allergens and pollutants or irritants that make asthma worse [A] • Consider allergen immunotherapy for patients with persistent asthma and when there is clear evidence of a relationship between symptoms and exposure to an allergen to which the patient is sensitive [B]. • Treat comorbid conditions (e.g., allergic bronchopulmonary aspergillosis [A], gastroesophageal reflux [B], obesity [B], obstructive sleep apnea [D], rhinitis and sinusitis [B], chronic stress or depression) [D] • Inactivated influenza vaccine for all patients over 6 months of age [A] unless contraindicated
	<p>Medications</p>	<ul style="list-style-type: none"> • Select medication and delivery devices to meet patient's needs. • Use a stepwise approach to pharmacologic therapy to gain and maintain asthma control [A]. (See age-specific guidelines.) • Inhaled corticosteroids (ICS) are the most effective long-term control therapy [A]. Optimize ICS use before advancing to other therapies. When choosing among treatment options, consider patient's impairment and risk, history of response to medication, willingness and ability to use medication.
	<p>Referral</p>	<ul style="list-style-type: none"> • Refer to an asthma specialist for consultation or comanagement if there are difficulties achieving or maintaining control (See age-specific guidelines.); immunotherapy or omalizumab is considered; additional testing is indicated; or if the patient required 2 bursts of oral systemic corticosteroids in the past year or a hospitalization [D].

Levels of Evidence for the most significant recommendations: A = randomized controlled trials; B = controlled trials; no randomization; C = observational studies; D = opinion of expert panel. This guideline lists core management steps. It is based on the 2007 National Asthma Education and Prevention Program Expert Panel Report 3, Guidelines for the Diagnosis and Management of Asthma, National Heart, Lung and Blood Institute (www.nhlbi.nih.gov). Individual patient considerations and advances in medical sciences may supersede or modify these recommendations.

Key Components		Assess Asthma Severity Recommendation and Level of Evidence							
First, assess severity to decide initial therapy		Intermittent	Step 1	Step 2	Step 3	Step 4	Step 5	Step 6	Persistent (Severe)
Components of Severity	Impairment	Symptoms Nighttime awakenings Short-acting beta ₂ -agonist use for symptoms Interference with normal activity	≤ 2 days/week 0 ≤ 2 days/week	> 2 days/week, not daily 1-2x/month > 2 days/week, not daily	Minor limitation	Some limitation	Daily 3 - 4x/month Daily	Daily 3 - 4x/month Daily	Throughout day > 1x/week Several times daily
	Risk	Exacerbations requiring oral steroids	None 0-1/year	≥ 2 in 6 months requiring oral steroids, or ≥ 4 in 1 year lasting > 1 day and have risk factors for persistent asthma	Consider severity & interval since last exacerbation. Frequency & severity may fluctuate over time for patient of any severity class.				Extremely limited
Recommended step for initiating treatment			Step 1	Step 2	Step 3				
Re-evaluate control in 2-6 weeks and adjust therapy accordingly.									
On follow-up, assess control and step therapy up or down	Components of Control	Well-Controlled	Assess Asthma Control						
	Impairment	Symptoms Nighttime awakenings Short-acting beta ₂ -agonist use for symptoms Interference with normal activity Exacerbations requiring oral steroids Treatment-related adverse effects	≤ 2 days/week, but not > 1 day ≤ 1x/month ≤ 2 days/week	> 2 days/week or many times on ≤ 2 days/week > 1x/month > 2 days/week	Not Well-Controlled	Very Poorly Controlled	Throughout day > 1x/week Several times daily	Throughout day > 1x/week Several times daily	Throughout day > 1x/week Several times daily
Risk	Exacerbations requiring oral steroids Treatment-related adverse effects	None 0-1x/year	Intensity of medication-related side effects does not correlate to specific levels of control, but should be considered in overall assessment of risk.	Some limitation 2-3x/year	Extremely limited > 3x/year				
Recommended treatment and follow-up		<ul style="list-style-type: none"> Maintain current step Regular follow-up every 1-6 months Consider step down if well-controlled ≥ 3 months 	Step up 1 step	<ul style="list-style-type: none"> Re-evaluate in 2-6 weeks If no clear benefit in 4-6 weeks, consider alternative diagnosis or adjust therapy [D] 					
Step approach for asthma management (Use lowest treatment level required to maintain control.)		<ul style="list-style-type: none"> Quick relief medication for all patients: Inhaled short-acting beta₂-agonist (SABA), as needed for symptoms. Intensity of treatment depends on severity of symptoms; up to 3 treatments at 20-minute intervals as needed. Short course of systemic oral corticosteroids may be needed. Use of SABA > 2 days a week for symptom control (not prevention of exercise-induced bronchospasm) indicates inadequate control and the need to step up treatment. Patient education and environmental control at each step Persistent asthma: Daily long-term control therapy [A]; consult with asthma specialist step 4 or higher [D]; consider consultation at step 3 [D] 							
Intermittent	Mild Persistent	Moderate Persistent	Severe Persistent						
Step 1	Step 2	Step 3	Step 4	Step 5	Step 6				
Preferred	Preferred	Preferred	Preferred	Preferred	Preferred				
Short-acting beta ₂ -agonist as required	Low-dose inhaled corticosteroid [A]	Medium-dose inhaled corticosteroid	Medium-dose inhaled corticosteroid + either a long-acting beta ₂ -agonist or montelukast [D]	High-dose inhaled corticosteroid + either a long-acting beta ₂ -agonist or montelukast [D]	High-dose inhaled corticosteroid + either a long-acting beta ₂ -agonist or montelukast [D]				
Alternative	Alternative	Alternative	Alternative	Alternative	Alternative				
Cromolyn or Montelukast [B]	Cromolyn or Montelukast [B]	Cromolyn or Montelukast [B]	Cromolyn or Montelukast [B]	Cromolyn or Montelukast [B]	Cromolyn or Montelukast [B]				

Levels of Evidence for the most significant recommendations: A = randomized controlled trials; B = controlled trials, no randomization; C = observational studies; D = opinion of expert panel. This guideline lists core management steps. It is based on the 2007 National Asthma Education and Prevention Program Expert Panel Report 3, Guidelines for the Diagnosis and Management of Asthma, National Heart, Lung and Blood Institute (www.nhlbi.nih.gov). Individual patient considerations and advances in medical science may supersede or modify these recommendations.

Management of Asthma in Youth 12 Years and Older and Adults

Key Components	Recommendation and Level of Evidence						
	Classification of Asthma Severity						
First, assess severity to decide initial therapy	Components of Severity Impairment	Intermittent Step 1	Mild Persistent Step 2	Moderate Persistent Step 3	Severe Persistent Step 5	Very Severe Persistent Step 6	
	Symptoms Slight awakenings Short-acting beta ₂ -agonist use for symptoms with normal activity Sleep function. FEV ₁ /FVC 60-80 years/70%	Intermittent ≤ 2 days/week ≤ 2 months ≤ 2 days/week	Mild Persistent > 2 days/week, not daily 3-4 symptoms, not > 1/day > 2 days/week, daily and not > 1/day	Moderate Persistent None Normal FEV ₁ between exacerbations > 80% Normal	Severe Persistent Some limitation 60%-80% Reduced 5% 2-2x/year	Very Severe Persistent Extreme limitation < 60% Reduced > 5%	
	Risk Exacerbations requiring oral steroids	0-1/year	> 80% Normal	Some limitation 60%-80%	Extreme limitation < 60%		
	Recommended step for initiating treatment	Step 1	Step 2	Step 3	Step 4 or 5		
	On follow-up, assess control and step therapy up or down	Classification of Asthma Control					
	Components of Control Impairment	Well-Controlled ≤ 2 days/week	Not Well-Controlled > 2 days/week	Very Poorly Controlled Throughout day	Step 4 or 5	Step 4 or 5	
	Symptoms Nighttime awakenings Short-acting beta ₂ -agonist use for symptoms Interference with normal activity FEV ₁ or Peak Flow	Well-Controlled ≤ 2 days/week	Not Well-Controlled 1 - 3x/week > 2 days/week	Very Poorly Controlled Throughout day Several times/week	Step 4 or 5	Step 4 or 5	
	Exacerbations requiring oral steroids	0-1/year	> 80%	Some limitation 60%-80%	Step 4 or 5	Step 4 or 5	
	Recommended action for treatment	Step 1	Step 2	Step 3	Step 4 or 5	Step 4 or 5	
	Feasibility of medication-related side effects does not correlate to specific levels of control, but should be considered in overall assessment of risk.	<ul style="list-style-type: none"> • Maintain current step • Regular follow-up every 1-6 months • Consider step down if well-controlled ≥ 3 months 					
	Step approach for asthma management (Use lowest treatment level required to maintain control)	<ul style="list-style-type: none"> • Quick relief medication for all patients: inhaled short-acting beta₂-agonist (SABA) as needed for symptoms (A), intensity of treatment depends on severity of symptoms; up to 3 treatments at 20-minute intervals as needed. Short course of systemic oral corticosteroids may be needed. Use of SABA > 2 days a week for symptom control (not prevention of exercise-induced bronchospasm) indicates inadequate control and the need to step up treatment. • Patient education and environmental control at each step • Persistent asthma: Daily (long-term) control therapy (A); consult with asthma specialist if step 4 or higher (D), or progressive decreased lung function. Consider consultation at step 3 (D). 					
	Preferred Short-acting beta ₂ -agonist as required	Preferred Low-dose inhaled corticosteroid (A) Alternative Cromolyn Or Leukotriene receptor antagonist; or Nedocromil; or Theophylline (B)	Preferred Low-dose inhaled corticosteroid + long-acting beta ₂ -agonist (A) or Medium-dose inhaled corticosteroid (A)	Preferred Medium-dose inhaled corticosteroid + long-acting beta ₂ -agonist (B) Alternative Medium-dose inhaled corticosteroid + either a leukotriene receptor antagonist (A), theophylline (B), or zileuton (D)	Preferred High-dose inhaled corticosteroid + long-acting beta ₂ -agonist (B) and consider omalizumab for patients who have IgE-mediated allergies (B)	Preferred High-dose inhaled corticosteroid + long-acting beta ₂ -agonist + oral corticosteroid (D) and consider omalizumab for patients who have IgE-mediated allergies (B)	

Levels of Evidence for the most significant recommendations: A = randomized controlled trials; B = controlled trials; no randomization; C = observational studies; D = opinion of expert panel. This guideline sets core management steps. It is based on the 2007 National Asthma Education and Prevention Program Expert Panel Report 3, Guidelines for the Diagnosis and Management of Asthma, National Heart, Lung and Blood Institute (www.nhlbi.nih.gov). Individual patient considerations and advances in medical science may necessitate modifications to these recommendations. Approved by NCI's National Director 07/08 www.mqic.org

The following guideline applies to patients with type 1 and type 2 diabetes mellitus. It recommends specific interventions for periodic medical assessment, laboratory tests and education to guide effective patient self-management.

Eligible Population	Key Components	Recommendation and Level of Evidence	Frequency
Patients 18-75 years of age with type 1 or type 2 diabetes mellitus	<p>Periodic assessment</p> <p>Laboratory tests</p> <p>Education, counseling and risk factor modification</p> <p>Medical recommendations</p>	<p>Assessment should include:</p> <ul style="list-style-type: none"> • Height, weight, BMI, blood pressure [A] (adult target of < 130/80) • Assess cardiovascular risks (smoking, hypertension, dyslipidemia, sedentary lifestyle, obesity, stress, family history, age > 40) • Comprehensive foot exam (including monofilament testing annually) [B] • Screen for depression [D] • Dilated eye exam by ophthalmologist or optometrist [B], or gliscope [B] <p>Tests should include:</p> <ul style="list-style-type: none"> • A1C [D] • Urine microalbumin measurement [D] • Serum creatinine and calculated GFR [D] • Fasting lipid profile • Comprehensive diabetes self-management education (DSME) from a collaborative team or diabetic educator if available <p>Education should be individualized, based on the National Standards for DSME [B] and include:</p> <ul style="list-style-type: none"> • Assessment of patient knowledge, attitude, self-management skills and health status; strategies for making health behavior changes and addressing psychosocial concerns [C] • Description of diabetes disease process and treatment; safe and effective use of medications; prevention, detection and treatment of acute and chronic complications • Importance of nutrition management and regular physical activity [A] • Role of self-monitoring of blood glucose in glycemic control [A] • Cardiovascular risk reduction • Smoking cessation intervention [B] and secondhand smoke avoidance [C] • Self-care of feet [B]; zinc/capitation counseling [D]; encourage patients to receive dental care [D] <p>Care should focus on smoking, hypertension, lipids and glycemic control:</p> <ul style="list-style-type: none"> • Medications for tobacco dependence unless contraindicated • Treatment of hypertension using up to 3-4 anti-hypertensive medications to achieve adult target of < 130 systolic [B] and < 80 diastolic [A] • Prescription of ACE inhibitor or angiotensin receptor blocker in patients with hypertension or albuminuria [A]² • Statin therapy for primary prevention against macrovascular complications in patients with diabetes who are ≥ age 40 or who have an LDL-C > 100 mg/dl [A]³ • Anti-platelet therapy [A]: low dose aspirin daily for primary prevention in adults at increased cardiovascular risk with type 1 [C] and type 2 [A] diabetes, unless contraindicated • Adjust the plan to eventually achieve normal or near-normal glycemia with an A1C goal for most patients of < 7%. Less stringent treatment goals may be appropriate for patients with a history of severe hypoglycemia, patients with limited life expectancies, very young children or older adults and individuals with comorbid conditions. More stringent treatment goals (i.e., a normal A1C < 6%) for individual patients and in pregnancy. Note: Insulin and sulfonylureas sometimes result in weight gain. <p>Assurance of appropriate immunization status (tetanus, diphtheria, pertussis, influenza, pneumococcal vaccine) [C]</p>	<ul style="list-style-type: none"> • At least annually and more frequently as needed • In the absence of retinopathy repeat in 2 years • A1C 2 - 4 times annually based on individual therapeutic goal; other tests at least annually • At diagnosis and as needed • At each visit until therapeutic goals are achieved

¹ See http://care.diabetesjournals.org/ce1031/Supplement_1/

² Consider referral of patients with serum creatinine value >2.0 mg/dl (adult value) or persistent albuminuria to nephrologist for evaluation.

³ Target LDL-C < 100 mg/dl [B]. For patients with overt CVD, a lower LDL-C goal of < 70 mg/dl is an option [B].

Levels of evidence for the most significant recommendations: A = randomized controlled trials; B = controlled trials; B = observational studies; D = opinion of expert panel. This guideline lists core management steps. It is based on several sources, including the 2008 American Diabetes Association Clinical Practice Recommendations (www.diabetes.org). Individual patient considerations and advances in medical science may supersede or modify these recommendations.

Michigan Quality Improvement Consortium Outpatient Management of Uncomplicated Deep Venous Thrombosis

Michigan Quality Improvement Consortium	Eligible Population	Key Components	Recommendation and Level of Evidence
<p>Adult patients ≥ 18 years of age</p> <p>Diagnosis of acute DVT, confirmed by duplex ultrasonography or venography. [A]</p> <p>No contraindications to anticoagulation or use of low molecular weight heparin (LMWH).</p>	<p>Initial assessment</p>	<ul style="list-style-type: none"> Perform initial comprehensive history and physical examination; consider conditions predisposing to DVT. Assess patient/caregiver ability and compliance for outpatient therapy, and need for home care resources. Assess for relative or absolute contraindications to outpatient anticoagulation therapy, including: <ul style="list-style-type: none"> • Pulmonary embolism • Extensive iliofemoral thrombus • Known potential for non-compliance • Active bleeding • Severe HTN • Catheter-associated DVT • Renal clearance <30 mL/min • Creatinine >2.5 mg/dL 	<ul style="list-style-type: none"> Thrombocytopenia $<100,000$ History of heparin induced thrombocytopenia
<p>Initiating and monitoring pharmacologic interventions</p>	<p>Initial assessment</p>	<ul style="list-style-type: none"> • Outpatient therapy is preferred if no contraindications. • Contraindications to warfarin therapy: <ul style="list-style-type: none"> Absolute: pregnancy Relative: dementia, certain psychoses, diminished mental capacity, or childbearing age without contraception • Begin LMWH. • Begin warfarin after 1st dose of LMWH [A], on the same day, titrate to INR range of 2.0 - 3.0. • Continue LMWH (along with warfarin) at least 5 days, and until INR range 2.0 - 3.0 for 2 consecutive days. [A] • Maintain warfarin therapy at least 3 months in therapeutic INR range [A], longer if risk of recurrence. • Ask about any changes in diet, medications, supplements and herbal products, and compliance before any dosage adjustment. • If known hypercoagulable state, consider referral to a coagulation specialist. 	<ul style="list-style-type: none"> • Obtain baseline lab values: aPTT, PT/INR, CBC with platelet count. Consider platelet count 3 to 5 days into anticoagulation therapy. • Monitor warfarin therapy using INR; no lab monitoring required for LMWH unless special circumstances such as renal insufficiency or extremes of body weight. • Frequent INR monitoring is necessary at the onset of warfarin therapy (e.g. at least 2 checks in the first week of therapy); then at least 2-3 times per week for the next 1-2 weeks. When stable, monitor every 4-8 weeks. • Monitor common bleeding sites; gums, nose, GI, GU and skin. • Monitor for signs/symptoms of pulmonary embolism, and medication side effects. • Maintain an Anticoagulant Monitoring Log (or dose adjustment system) for each patient treated with warfarin. • Management through a systematic program is essential (either in office or a specialized program for anticoagulation monitoring).
<p>Testing/Monitoring</p>	<p>Testing/Monitoring</p>	<p>Testing/Monitoring</p>	<ul style="list-style-type: none"> • Inform patient/caregiver of the reasons and benefits of therapy, potential side effects, importance of follow-up monitoring, warfarin dosage adjustment, compliance, dietary recommendations (i.e. a diet that is constant in vitamin K), the potential for drug interactions, safety precautions, recognizing internal bleeding, and risk of hormonal contraception/therapies. • Instruct patient/caregiver on symptoms of pulmonary embolism, extension of DVT and self-injection of LMWH. • The patient should be encouraged to be ambulatory after an appropriate weight-based dose of LMWH [D]. • Compression stockings should be used routinely to prevent post-thrombotic syndrome [A], beginning as soon as possible of the diagnosis of DVT and continuing for a minimum of 2 years. If stockings cannot be used initially due to swelling, compression wraps should be used until it is possible to use stockings.
<p>Patient education</p>	<p>Patient education</p>	<p>Patient education</p>	<ul style="list-style-type: none"> • Inform patient/caregiver of the reasons and benefits of therapy, potential side effects, importance of follow-up monitoring, warfarin dosage adjustment, compliance, dietary recommendations (i.e. a diet that is constant in vitamin K), the potential for drug interactions, safety precautions, recognizing internal bleeding, and risk of hormonal contraception/therapies. • Instruct patient/caregiver on symptoms of pulmonary embolism, extension of DVT and self-injection of LMWH. • The patient should be encouraged to be ambulatory after an appropriate weight-based dose of LMWH [D]. • Compression stockings should be used routinely to prevent post-thrombotic syndrome [A], beginning as soon as possible of the diagnosis of DVT and continuing for a minimum of 2 years. If stockings cannot be used initially due to swelling, compression wraps should be used until it is possible to use stockings.

Levels of Evidence for the most significant recommendations: A = randomized controlled trials; B = controlled trials, no randomization; C = observational studies; D = opinion of expert panel

This guideline represents core management steps. It is based on several sources including: Management of Venous Thromboembolism: A Clinical Practice Guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Intern Med. 2007;146:204-10, and New Antithrombotic Drugs. American College of Chest Physicians. CHEST 2008;133:23AS-26SS. Individual patient considerations and advances in medical science may supersede or modify these recommendations.



Michigan Quality Improvement Consortium Guideline

Adults with Systolic Heart Failure

The following guideline recommends diagnostic evaluation, pharmacologic treatment and education that support effective patient self-management.

Eligible Population		Key Components	Recommendation and Level of Evidence
Adults with suspicion of left-ventricular systolic dysfunction, including heart failure	Evaluation	<ul style="list-style-type: none"> Initial assessment should include: <ul style="list-style-type: none"> • Thorough history and physical examination [C] • Depression screening • Assessment for coronary artery disease and risk factors • Chest X-ray [C] • 12-lead electrocardiogram [C] • Lipid profile, CBC, electrolytes, calcium, magnesium, BUN, creatinine, blood glucose, liver function tests, TSH, urinalysis [C] • Two-dimensional echocardiography with Doppler [C] • Serial monitoring should include: weight, volume status, electrolytes, renal function and activity tolerance. 	
Adults diagnosed with left-ventricular systolic dysfunction, including heart failure	Pharmacological management	<ul style="list-style-type: none"> Drugs recommended for routine use: <ul style="list-style-type: none"> • ACE inhibitors in all patients, unless contraindicated¹ [A] • Recommend beta-blockers (carvedilol, sustained-release metoprolol, bisoprolol) in all stable patients, unless contraindicated^{1,2} [A] Drugs recommended for use in select patients: <ul style="list-style-type: none"> • Diuretics and sodium restriction for evidence of fluid retention [A] • Spironolactone for patients with moderate or severe symptoms of heart failure, preserved renal function (creatinine < 2.0 in women; creatinine < 2.5 in men) and normal serum potassium concentration [A] • In patients who cannot tolerate ACE inhibitors due to cough or angioedema, angiotensin receptor blockers are recommended [A]. • In patients who cannot tolerate ACE inhibitors or ARBs due to angioedema or renal insufficiency, hydralazine and nitrate combination is recommended [A]. • African-American patients who remain symptomatic despite therapy with ACE inhibitors, beta-blockers and PRN diuretics, may be candidates for adding the combination of hydralazine and isosorbide dinitrate [A]. 	
	Education, counseling and risk factor modification	<ul style="list-style-type: none"> Educate patient and family regarding: <ul style="list-style-type: none"> • Daily self-monitoring of weight and adherence to recommended patient action plan • Recognition of symptoms and when to seek medical attention • Moderate dietary sodium restriction (e.g., 2,000-2,500 mg sodium/day) • Risk factor modification (regular exercise 5 times per week as tolerated [B]; smoking cessation; control of BP, DM, lipids) • Avoid excessive alcohol intake, illicit drug use, and the use of NSAIDs • Vaccination against influenza and pneumococcal disease 	

¹ Contraindications include: life-threatening adverse reactions (angioedema or anuric renal failure), pregnancy, hypotensive patients at immediate risk of cardiogenic shock, systolic blood pressure < 80 mm Hg, serum creatinine > 3 mg/dL, bilateral renal artery stenosis, or serum potassium > 5.5 mmol/L.

² Contraindications include: patients with current or recent fluid retention history, unstable or poorly controlled reactive airway disease, symptomatic bradycardia or advanced heart block (unless treated with a pacemaker), or recent treatment with an intravenous positive inotropic agent.

Levels of Evidence for the most significant recommendations: A = randomized controlled trials; B = controlled trials, no randomization; C = observational studies; D = opinion of expert panel

This guideline lists core management steps. It is based on the ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (www.acc.org). Individual patient considerations and advances in medical science may supersede or modify these recommendations.



Michigan Quality Improvement Consortium Guideline Screening and Management of Hypercholesterolemia

The following guideline recommends risk assessment, stratification, education, counseling and pharmacological interventions for the management of low-density lipoprotein cholesterol (LDL-C)

Eligible Population	Key Components	Recommendation and Level of Evidence
Age ≥ 18 years	Risk Assessment	<ul style="list-style-type: none"> • Screening: Initial fasting lipid profile (i.e., total, LDL-C, HDL-C, triglycerides); If normal, repeat at least every five years; [D] • Treatment is based on LDL-C, major risk factors and presence of CHD or equivalent.
	<p>Major Risk Factors:</p> <ul style="list-style-type: none"> • Cigarette smoking • Hypertension (BP ≥ 140/90) • On antihypertensives, regardless of current BP levels • HDL-C: < 40 (HDL-C ≥ 60 = negative risk factor) • Family history (first degree) of premature CHD (men < 55 years; women < 65 years) • Age (men ≥ 45 years; women ≥ 55 years) 	<p>CHD Risk Equivalents:</p> <ul style="list-style-type: none"> • Other clinical forms of atherosclerotic disease (e.g., peripheral arterial disease, abdominal aortic aneurysm, and/or symptomatic carotid artery disease) • Diabetes plus one additional risk factor (diabetes alone is not considered a risk equivalent) • Multiple risk factors confer a 10-year risk for CHD > 20% • CHD and CHD risk equivalents give a > 20% risk of a CHD event within 10 years
	<p>Risk Stratification</p>	<ul style="list-style-type: none"> • Calculate short-term risk for patients with 2+ risk factors using Framingham projection of 10-year absolute risk [D]: <p>Goal for LDL-C</p> <ul style="list-style-type: none"> • < 100 mg/dl <p>Categorical Risk</p> <ul style="list-style-type: none"> • CHD or CHD risk equivalents • 10-year risk: > 20% • 2+ risk factors • 10-year risk: ≤ 20% • 0 - 1 risk factor
	<p>Education and risk factor modification</p>	<p>Educate patient/family regarding Therapeutic Lifestyle Changes (TLC):</p> <ul style="list-style-type: none"> • Reduce saturated fats and cholesterol [A], increase plant stanols/sterol (e.g. cholesterol-lowering margarines), increase viscous soluble fiber (e.g. oats, barley, lentils, beans), consider increasing fish consumption (Omega-3 fatty acids). • Decrease weight and increase exercise to moderate level of activity for 30 minutes, most days of the week [A].
	<p>Pharmacologic interventions</p>	<ul style="list-style-type: none"> • TLC and/or drug therapy may be initiated based on the LDL-C level and/or presence of CHD risk or CHD risk factors. • Initiate statin therapy for patients with CHD, CHD risk equivalents, or if the LDL-C is not at goal by 3 months after TLC have begun in earnest. • Statins are the most commonly used lipid-lowering agents. Liver function test monitoring is recommended at 3 months following treatment initiation, or dosage increases, or any statin. For prolonged myalgias, consider dosage reduction or statin change. • Evaluate and adjust drug therapy every 3 months until goal achieved. • For patients who do not reach LDL-C goal, consider referral to lipid specialist.

*Not all national guidelines agree

Levels of Evidence for the most significant recommendations: A = randomized controlled trials; B = controlled trials, no randomization; C = observational studies; D = opinion of expert panel. This guideline represents core management steps. It is based on several sources including: Lipid Management in Adults, Institute for Clinical Systems Improvement, 2007 (iclsi.org). Individual patient considerations and advances in medical science may supersede or modify these recommendations.



Michigan Quality Improvement Consortium Guideline Medical Management of Adults with Hypertension

The following guideline recommends diagnosis, education and pharmacologic treatment that support effective patient self-management.	
Eligible Population	Recommendation and Level of Evidence
<p>Adult patients ≥ 18 years of age. Not pregnant.</p> <p>Classification based on mean of 2 or more seated BP readings on each of 2 or more office visits.</p> <p>Normal BP $<120/80$</p> <p>Prehypertension 120-130/80-89</p> <p>Hypertension: Stage 1 140-159/90-99 Stage 2 $\geq 160/100$</p>	<p>Key Components</p> <p>Initial assessment</p> <ul style="list-style-type: none"> The objectives of the initial evaluation are to assess lifestyle, cardiovascular risk, factors, concomitant disorders, reveal identifiable causes of hypertension and check for target organ damage and cardiovascular disease. Physical examination: 2 or more BP measurements using regularly calibrated equipment with the appropriate sized cuff and separated by at least 2 minutes, verification in contralateral arm, tuncoscopic exam, neck exam (bruits), heart and lung exam, abdominal exam for bruits or aortic aneurysm, extremity pulses. [A] Laboratory tests prior to initiating therapy: Potassium, creatinine, glucose, hematocrit, calcium, urinalysis, lipid panel, EKG. [D] <p>Patient education and nonpharmacologic interventions</p> <ul style="list-style-type: none"> Lifestyle modification: weight reduction (BMI goal <25), reduction of dietary sodium to less than 2.4 gm/day, DASH diet [A] (i.e. diet high in fruits and vegetables, reduced saturated and total fat), aerobic physical activity ≥ 30 minutes most days of the week, tobacco avoidance, increased dietary potassium and calcium, moderation of alcohol consumption. [A] Use of self BP monitoring. Check accuracy of home measurement device regularly. Mean self measured BP $> 135/85$ generally considered to be hypertensive. <p>Goals of Therapy</p> <ul style="list-style-type: none"> If no other risk factors: target BP $<140/90$. Patients with risk factors: target BP $<140/80$ ($<130/80$ for patients with diabetes or kidney disease). [D] Caution: low diastolic or orthostatic symptoms may limit ability to control systolic. Use extreme caution if diastolic is below 60. For diabetics, mortality increases if diastolic is below 70. <p>Pharmacologic interventions</p> <ul style="list-style-type: none"> Hypertension, Stage 1 (140-159/90-99): start with thiazide-type diuretics for most patients. ACE-I and long-acting DHP-CCB² (e.g. amlodipine) are first-choice additional agents. Hypertension, Stage 2 ($\geq 160/100$): consider two-drug combination (thiazide plus ACE-I or DHP-CCB²). In general, diuretics and DHP-CCB² appear to be more effective as an initial treatment in African-Americans. ACE-I recommended in patients with diabetes or heart failure. [A] Beta-blockers are recommended in patients with ischemic heart disease or heart failure. Use angiotensin-receptor blockers (ARB) if ACE-I not tolerated. Intensify treatment until treatment goals are met; 3 or more drugs may be necessary for some patients to achieve goal BP. Caution: NSAIDs may complicate management of hypertension and worsen renal function.
<p>Monitoring and adjustment of therapy [D]</p>	<ul style="list-style-type: none"> Prehypertension without other risk factors: annual BP check with lifestyle modification counselling. Hypertension, Stage 1: initiate therapy and recheck at monthly intervals until goal is reached. Hypertension, Stage 2: initiate therapy and recheck weekly or more often if indicated. Symptomatic Stage 2 may require hospital monitoring and treatment. Modify antihypertensive therapy as needed if adverse effects become intolerable. Once BP controlled with medication: recheck every 3-6 months. Check serum potassium and creatinine at least 1-2 times/year for patients on diuretics/ACE-I/ARB.

¹Moderate alcohol consumption is generally defined as up to two drinks per day for men, one drink per day for women.

²DHP-CCB = long-acting dihydropyridine calcium channel blocker (e.g. amlodipine, felodipine)

Levels of Evidence for the most significant recommendations: A = randomized controlled trials; B = controlled trials; C = observational studies; D = opinion of expert panel. This guideline represents core management steps. It is based on several sources including: Hypertension Diagnosis and Treatment, Institute for Clinical Systems Improvement, November 2008 (iCSI.org). Individual patient considerations and advances in medical science may supersede or modify these recommendations.

Michigan Quality Improvement Consortium Guideline Diagnosis and Management of Adults with Chronic Kidney Disease

The following guideline recommends diagnosis and aggressive management of chronic kidney disease by clinical stage.

Eligible Population	Key Components Screening & Diagnosis	Recommendation and Level of Evidence	Frequency
All adults at increased risk for CKD	Risk Factor Management & Patient Education	For patients at increased risk for CKD (e.g., diabetes, hypertension, family history of kidney failure, kidney stones, etc.) assess for markers of kidney damage:	<ul style="list-style-type: none"> • Semi-annual blood pressure monitoring; more frequent monitoring if indicated • Monitor GFR every 1-2 years
		<ul style="list-style-type: none"> • Measure blood pressure [A] • Obtain estimated GFR¹ (serum creatinine levels should not be used as sole means to assess renal function) • Protein-to-creatinine ratio or albumin-to-creatinine ratio (first morning or random spot urine specimen) • Urinalysis, fasting lipid profile, electrolytes, BUN • Evaluation and management of comorbid conditions (e.g. diabetes, hypertension, urinary tract obstruction, cardiovascular disease)² • Review medications for dose adjustment, drug interactions, adverse effects, therapeutic levels • Educate on therapeutic lifestyle changes: dietary sodium intake < 2.4 g/d recommended for patients with CKD and hypertension [A], weight maintenance if BMI < 25, weight loss if BMI ≥ 25; exercise and physical activity, moderation of alcohol intake, smoking cessation 	
Adults with CKD		<p>All of the above plus:</p> <ul style="list-style-type: none"> • Develop clinical action plan for each patient, based on disease stage as defined by the National Kidney Foundation, Kidney Disease Outcomes Quality Initiative (K/DOQI) [B] • Incorporate self-management behaviors into treatment plan at all stages of CKD [B] <p>Core Principles of Treatment</p> <ul style="list-style-type: none"> • Stage 1 (GFR ≥ 90): Monitor GFR annually, smoking cessation, consider ASA, consider ACE and/or ARB therapy, BP goal <130/80, LDL-C goal < 100 • Stage 2 (GFR 60-89): Nephrology referral if GFR decline > 4ml/min/1.73m², maintain BP and lipid goals as above • Stage 3 (GFR 30-59): Consult Nephrologist and Renal Dietician; Suppress PTH with Vit D to level appropriate for CKD stage; Phosphorus lowering treatment if > 4.6 mg/dl; Correct iron deficiency before start of erythropoiesis stimulating agent (ESA); ESA if Hgb (Hct) < 10 (30%); Renal-specific vitamins; Update vaccines: HBV, influenza, Tdap and Pneumovax • Stage 4 (GFR 15-29): Nephrology and vascular access surgery referrals, ESA if Hgb < 10 g/dL, Optimize Ca x P product to < 55 with specific agents, update vaccines as indicated, CKD education classes • Stage 5 (GFR < 15): Renal replacement therapy 	As indicated

¹ If not calculated by lab, refer to the National Kidney Foundation website for GFR calculator (<http://www.kidney.org/professionals/foolst/>)

² Reference MOIC guidelines on diabetes, hypertension, hyperlipidemia and obesity (www.mqic.org).

Levels of Evidence for the most significant recommendations: A = randomized controlled trials; B = controlled trials, no randomization; C = observational studies; D = opinion of expert panel. This guideline lists core management steps. It is based on the Henry Ford Health System, Divisions of Nephrology & Hypertension and General Internal Medicine Chronic Kidney Disease (CKD) Clinical Practice Recommendations for Primary Care Physicians and Healthcare Providers, Edition 5.0 (www.ghsrenal.com). Individual patient considerations and advances in medical science may supersede or modify these recommendations.



Michigan Quality Improvement Consortium Guideline Tobacco Control

The following guideline recommends specific interventions for cessation services for current smokers and tobacco users.

Eligible Population	Key Components	Recommendation and Level of Evidence	Frequency
All patients 12 years of age and older (regardless of prior use status)	Identification of tobacco use and exposure status (never, former, current) and type (all forms, including smokeless tobacco, pipe, snuff, cigars, hookah [water pipe] and second hand smoke)	<ul style="list-style-type: none"> • Ask and document tobacco use status in the medical record and/or problem list. [A] 	At each outpatient visit and inpatient admission
All patients identified as current smokers/tobacco users	Intervention to promote cessation of tobacco use	<ul style="list-style-type: none"> • Advise to quit [A] avoid second-hand smoke. • Assess patient willingness to attempt to quit. [C] • Assist patients who are ready to quit by: <ul style="list-style-type: none"> - Establishing a quit date. - Providing self-help materials (e.g., Free Quit Kits; see (www.michigan.gov/tobacco). - Offering nicotine replacement therapy (adults only) and/or non-nicotine medications e.g., sustained release bupropion [A] (adolescents and adults). - Recommending a smoking cessation program (e.g. MI Quit Line 1-800-480-7848 or your preferred program). - The combination of medication plus a smoking cessation program is more effective than either alone. [A] • Arrange follow-up contact, either in person or by telephone [D]: <ul style="list-style-type: none"> First week after quit date. First month after quit date. 	At each periodic health exam, more frequently at the discretion of the physician

SPECIAL CIRCUMSTANCES

- **Pregnant Smokers:** Due to the serious risks to the mother and fetus, pregnant smokers should be offered interventions such as referral to a smoking cessation program.
- **Hospitalized Smokers:** Clinicians should provide appropriate pharmacotherapy and counseling during hospitalization to reduce nicotine withdrawal symptoms and assist smokers in quitting.
- **Smokers with Psychiatric Comorbidity:** Nicotine withdrawal symptoms may exacerbate depression among patients with a prior history of affective disorder. Stopping smoking may affect the pharmacokinetics of certain psychiatric agents. Clinicians should monitor closely the actions or side effects of psychiatric medications in smokers/tobacco users who are attempting to quit.

Levels of Evidence for the most significant recommendations: A = randomized controlled trials; B = controlled trials, no randomization; C = observational studies; D = opinion of expert panel

This guideline lists core management steps. It is based on several sources including the Clinical Practice Guideline for the Management of Tobacco Use, Veterans Health Administration/Department of Defense, 2004 (cop.med.va.gov). Individual patient considerations and advances in medical science may supersede or modify these recommendations.



Michigan Quality Improvement Consortium Guideline Management of Overweight and Obesity in the Adult

The following guideline recommends specific interventions for treatment of overweight and obese conditions in adults.		
Eligible Population	Key Components	Frequency
Adults 18 years or older	Assessment of Body Mass Index (BMI)	At each periodic health exam; more frequently at the discretion of the physician
Patients with BMI ≥ 25	Interventions to promote weight management	At each periodic health exam; more frequently when possible
Patients with BMI > 30 or > 27 with other risk factors or diseases	Interventions to promote weight management	At each periodic health exam; more frequently when possible
BMI ≥ 40 or BMI ≥ 35 with uncontrolled ³ comorbid conditions ³	Surgical treatment	At each periodic health exam; more frequently when possible

Recommendation and Level of Evidence

- Measure height and weight, and calculate patient's BMI¹ to determine if patient is overweight or obese, and pattern of weight change [C].
 - If overweight, assess for complicating risk factors:
 - Hypertension
 - Family history of premature CHD
 - Presence of atherosclerotic disease
 - Diabetes mellitus
 - Sleep apnea
 - High triglycerides, high LDL or low HDL
 - Impaired fasting glucose
 - Smoking
 - Assess current eating, exercise behaviors, history of weight loss attempts and psychological factors or medications that contribute to weight gain².
 - **Help your patients establish their own realistic lifestyle goals³:**
 - **Help your patient set a realistic goal for reducing calories and adjusting to maintain gradual weight loss(A), ideally to maintain a 1- to 2-pound weight loss per week and improve dietary quality.**
 - Help your patient set a realistic goal for physical activity: at a minimum, more activity than present; ideally 30 minutes of moderate physical activity most days of the week (A).
 - Recommend weight loss strategies and resources as needed. (See www.michigan.gov/surgeongeneral)
 - Arrange follow-up with patients to monitor progress and provide support.
- All of the above plus:**
- Consider referral to a program that provides guidance on nutrition, physical activity and psychosocial concerns.
 - Consider pharmacotherapy only for patients with increased medical risk because of their weight with co-existing risk factors or comorbidities (monitor for weight loss and medication side effects; periodically review need for medication).
 - Insurance coverage for weight loss medications varies; consult health plan for eligibility.
- Weight loss surgery should be considered⁴ only for patients in whom other methods of treatment have failed and who have clinically severe obesity, i.e., BMI ≥ 40 or BMI ≥ 35 with life-threatening comorbid conditions⁵ [B].
- Evaluate for psychological readiness for surgical intervention and post-surgical lifestyle commitment.

¹ BMI is an accurate proxy for body fat in average adults but may be misleading in muscular individuals.

² Weight gain may be associated with medications: antidiabetics, SSRI and tricyclic antidepressants, atypical antipsychotics, anticonvulsants, beta-blockers and corticosteroids.

³ Avoid weight gain or maintain weight loss, initial goal of 10% weight loss and reassess after goal achieved, maximum weight loss of 12 pound per week if overweight and 1-2 pounds per week if BMI > 30 .

⁴ Insurance coverage for bariatric surgery varies; consult health plan for eligibility.

⁵ Comorbidities: Severe cardiac disease (CHD, pulmonary hypertension, congestive heart failure, and cardiomyopathy); Type 2 diabetes; obstructive sleep apnea and other respiratory disease (chronic asthma) hypoventilation syndrome, Pickwickian syndrome); end-organ damage; pseudo-tumor cerebri; gastroesophageal reflux disease; hypertension; hyperlipidemia; severe joint or disc disease if interferes with daily functioning

Levels of Evidence for the most significant recommendations: A = randomized controlled trials; B = controlled trials, no randomization; C = observational studies; D = opinion of expert panel
This guideline represents core management steps. It is based on the Prevention and Management of Obesity (Mature Adolescents and Adults), Institute for Clinical Systems Improvement, 2006; and the National Institutes of Health, National Heart, Lung and Blood Institute Obesity Education Initiative, The Practical Guide: Identification, Evaluation and Treatment of Overweight and Obesity in Adults, 2000 (www.nhlb.nih.gov). Individual patient considerations and advances in medical science may supersede or modify these recommendations.

Michigan Quality Improvement Consortium Treatment of Childhood Overweight and Obesity



The following guideline recommends specific treatment interventions for childhood overweight and obesity.

Eligible Population	Key Components	Recommendation and Level of Evidence	Frequency
Children 2 years or older with a BMI \geq 85th percentile	Identify presence of weight related risk factors and complications	<p>Reinforce Prevention Recommendations (See also <i>MOIC Prevention and Identification of Childhood Overweight Guideline</i>)</p> <ul style="list-style-type: none"> • History and physical exam [D]; • Family history, evaluate general comorbidities, including but not limited to cardiovascular disease and diabetes • History of medication use including nutritional supplements • Symptoms of gallbladder disease, Type 2 diabetes, obstructive sleep disorders, hypothyroidism • Presence of acanthosis nigricans • Weight-related orthopedic problems • Pulse and blood pressure, using appropriate technique and cuff size for age • Be alert to secondary causes of obesity. If aberrant findings are noted (short stature, hypotonia, hirsutism, etc.) then consider genetic and other endogenous causes of obesity. • Patient or parental concern about weight • Testing: Annual lipid profile and fasting glucose 	Each periodic health exam, more frequently as case requires
Children 2 years or older with a BMI \geq 85th-94th percentile (overweight) without risk factors or complications	Lifestyle intervention to reach weight maintenance	<p>Consider all of the above, plus:</p> <p>Intervention to promote weight management/treatment [D]:</p> <ul style="list-style-type: none"> • Reinforce lifestyle intervention and behavior modification. Focus is appropriate weight maintenance. • Family must be involved; small gradual changes are recommended towards the stated goal • Monitor for increasing BMI percentile • Monitor for the development of risk factors or complications 	Consider management of childhood obesity as a medium- to long-term intervention
Children 2 years or older with a BMI \geq 85th-94th percentile with risk factors or complications	Lifestyle intervention with treatment of risk factors and complications as needed	<p>All of the above, plus:</p> <ul style="list-style-type: none"> • Primary goal of childhood weight interventions is regulation of body weight and fat with adequate nutrition for growth and development. • Treat risk factors and complications as needed. • Substantial slowing of weight gain may be achieved by relatively small but consistent changes in energy (200-500 kcal/day) intake, expenditure or both. If weight loss is desired, an appropriate starting goal is about 1 lb of weight loss per month. • Consider referral to multidisciplinary pediatric obesity treatment center, pediatric endocrinologist or registered dietitian. 	
Children 2 years or older with BMI \geq 95th percentile (obese) with or without risk factors or complications	Weight loss with concomitant treatment of risk factors and complications as needed	<p>All of the above, plus:</p> <ul style="list-style-type: none"> • Long-term goal should be a body mass index below 85th percentile for age and sex. • Consider aggressive approach to weight loss and treatment for patients after conservative approaches have failed. • Consider AST, ALT, BUN and creatinine. 	

Levels of Evidence for the most significant recommendation: A = randomized controlled trials; B = controlled trials, no randomization; C = observational studies; D = opinion of expert panel
This guideline lists core management steps. It is based on several sources, including: the American Medical Association 2007 Expert Committee Recommendations on the Treatment of Pediatric Obesity (www.ama-assn.org). Individual patient circumstances and advances in medical science may supersede or modify these recommendations.

Approved by **MOIC Medical Directors 06/08**

www.moic.org

Michigan Quality Improvement Consortium Guideline Prevention and Identification of Childhood Overweight

June, 2008

The following guideline recommends specific interventions for prevention and identification of childhood overweight and obesity.		Recommendation and Level of Evidence	Frequency
Eligible Population Parents of children younger than 2 years old	Key Components Education of parents regarding obesity and prevention of risk	<p>Prevention to promote healthy weight:</p> <ul style="list-style-type: none"> • Encourage breastfeeding; discourage overfeeding of bottle fed infants [A]. • Avoid premature introduction of solids and base timing for introduction of solids on child's development, usually between 4 months and 6 months of age. • Preserve natural satiety by respecting a child's appetite. • Educate caregivers on the importance of age-specific meals and snacks, consistent mealtimes, appropriate snacking, serving sizes, reading nutritional labeling and daily physical activity. • Educate parents about the importance of parental role modeling for healthy lifestyle behaviors and of parental controls [D]. • Avoid high-calorie, nutrient-poor beverages (e.g., soda, fruit punch or any juice drink less than 100% juice). • Limit intake of 100% juice to <6 oz per day; may offer in a cup, starting at 6 months of age. • Evaluate general comorbidities, including but not limited to cardiovascular disease of parents. • No television or computer screen time [D]. <p>General assessment:</p> <ul style="list-style-type: none"> • History (including focused family history) and physical exam • Measure and record weight and height on CDC BM-for-age growth chart, calculate and plot patients' BMI [weight (kg)/height squared (m²) or (pounds x 703)/inches²].¹ • Dietary patterns (e.g. frequency of eating outside the home, consumption of breakfast, adequate fruits and vegetables, excessive portion sizes, etc). • Risk factors for overweight² including pattern of weight change [C]. Watch for increases of 3-4 BMI units/year 	At each periodic health exam
Children 2 years or older	Assessment of body mass index, risk factors for overweight and excessive weight gain relative to linear growth	<p>Preschool:</p> <ul style="list-style-type: none"> • Limit television and computer screen time to 1-2 hours per day, remove television and computer screens from primary sleeping area. • Replace whole milk with skim, avoid high-calorie, nutrient-poor beverages (soda, fruit punch, juice drinks); limit intake of 100% juice. • Eat breakfast daily; limit eating out and portion sizes, particularly fast foods. • Promote a healthy diet (include fruit and vegetables and low-fat dairy) that encourages family mealtimes, regular eating times and minimizes nutritionally poor food prepared outside the home. • Respect the child's appetite and allow him or her to self-regulate food intake. • Provide structure and boundaries around healthy eating with adult supervision. • Promote physical activity including unstructured play at home, during child care and in the community. <p>School-aged, the above plus:</p> <ul style="list-style-type: none"> • Accumulate at least 60 minutes, and up to several hours, of age-appropriate physical activity on all or most days of the week (emphasize lifestyle exercise, i.e., outdoor play, yard work, and household chores). • Consider barriers (e.g., social support, unsafe neighborhoods or lack of school-based physical education) and explore individualized solutions. • Reinforce making healthy food and physical activity choices at home and outside of parental influence. 	
Children 2 years or older, BMI for age < 85th percentile	Prevention to promote healthy weight		

¹ See <http://aapa.nccdc.gov/epidemiologicupdate.aspx>

² Low or high birth weight, low income, minority, television or computer screen time > 2 hrs, low physical activity, poor eating, depression

Levels of evidence by the most significant recommendations: A = randomized controlled trials; B = controlled trials, no randomization; C = observational studies; D = opinion of expert panel
 This guideline lists core management steps. It is based on several sources, including the American Medical Association 2007 Expert Committee Recommendations on the Treatment of Pediatric Obesity (www.ama-assn.org). Individual patient considerations and advances in medical science may supersede or modify these recommendations.



Michigan Quality Improvement Consortium Guideline Medical Management of Adults with Osteoarthritis

The following guideline recommends initial evaluation, nonpharmacologic and pharmacologic interventions for the management of osteoarthritis.

Eligible Population	Key Components	Recommendation and Level of Evidence
Adults with clinical suspicion or confirmed diagnosis of osteoarthritis	Initial evaluation	<ul style="list-style-type: none"> Detailed history (aspirin use, pain control with over-the-counter medications, activity tolerance and limitations) Physical examination Assess gastrointestinal (GI) risk: <ul style="list-style-type: none"> History of GI bleeding History of peptic ulcer disease and/or non-steroidal induced GI symptoms Concomitant use of corticosteroids and/or warfarin (A) High dose, chronic, or multiple NSAIDs including aspirin Age > 60 yrs
	Nonpharmacologic modalities	<p>Treatment plan should include:</p> <ul style="list-style-type: none"> education and counseling regarding weight reduction and joint protection range-of-motion (B), aerobic and muscle strengthening exercises for patients with functional limitations, consider physical and occupational therapy self-management resources (e.g., American Arthritis Foundation self help course and book) <p>For select patients:</p> <ul style="list-style-type: none"> assistive devices for ambulation and activities of daily living appropriate footwear, orthotics (e.g., wedged insoles)
		Pharmacologic Therapy
Therapies other than NSAIDs		<ul style="list-style-type: none"> Initial drug of choice: Acetaminophen at maximum recommended dose, modify dose for patients at risk for toxicity (note patients with hepatic toxicity risk factors, especially those on aspirin, or warfarin). Warn patients that many over the counter products contain acetaminophen and to monitor dose carefully. Topical capsaicin
NSAID analgesics:	No or low NSAID GI risk	NSAID GI risk
<ul style="list-style-type: none"> No cardiovascular risk 	<ul style="list-style-type: none"> NSAID Add PPI¹ if on aspirin, plus risk warrants GI protection 	<ul style="list-style-type: none"> NSAID plus PPI¹ If NSAID not-tolerated, Cyclo-oxygenase-2 (COX-2) selective inhibitor For those with prior GI bleed avoid all NSAIDs/COX-2, if must use, then COX-2 plus PPI¹ [D]
<ul style="list-style-type: none"> Cardiovascular risk 	<ul style="list-style-type: none"> Naproxen^{2,3} Add PPI¹ if GI risk of aspirin/NSAID combination warrants GI protection 	<ul style="list-style-type: none"> Naproxen^{2,3} plus PPI¹ if cardiovascular risk > GI risk COX-2 plus PPI¹ if GI risk > cardiovascular risk
Other pharmacologic agents	<ul style="list-style-type: none"> Nonacetylated salicylate, tramadol, opioids, intra-articular glucocorticoids or hyaluronate, lidoderm or methylsalicylate 	

¹ Mesoprostol at full dose (800 µg four times a day) may be substituted for PPI.

² Naproxen probably has lowest cardiovascular risk of NSAID/COX-2 class.

³ If aspirin is used daily, COX-2 offers no advantage over NSAID.

Levels of Evidence for the most significant recommendations: A = randomized controlled trials; B = controlled trials, nonrandomized; C = observational studies; D = opinion of expert panel. This guideline lists core management steps and is based on the following sources: The ICSI Diagnosis and Treatment of Adult Degenerative Joint Disease (DJD)/Osteoarthritis (OA) of the Knee, Institute for Clinical Systems Improvement, 2007 (icis.org) and Schierman JM. Summing the Risk of NSAID Therapy. Lancet 2007; 369:1560-1. Individual patient considerations and advances in medical science may supersede or modify these recommendations.

Michigan Quality Improvement Consortium
Management of Acute Low Back Pain

The following guideline recommends assessment, diagnosis and treatment interventions for the management of acute low back pain in adults.

Eligible Population	Key Components	Recommendation and Level of Evidence
Adults with low back pain or back-related leg symptoms for < 6 weeks	Patients with low risk of serious pathology (no red flags)	<p>Reassure patient that 90% of episodes resolve within six weeks regardless of treatment [C]. Advise that minor flare-ups may occur in the subsequent year.</p> <p>Therapy:</p> <ul style="list-style-type: none"> Stay active and continue ordinary activity within the limits permitted by pain. Avoid bedrest [A]. Early return to work is associated with less disability. Injury prevention (e.g. use of proper body mechanics, safe back exercises) Recommend ice for painful areas and stretching exercises [D]. McKenzie exercises [A] are helpful for pain radiating below the knee. <p>Referral:</p> <ul style="list-style-type: none"> If no improvement at 1-2 weeks, refer for goal-directed manual physical therapy, not modalities such as heat, traction, ultrasound, TENS. Surgical referral usually not required if no "red flags." <p>Medication Strategies:</p> <ul style="list-style-type: none"> Medication treatment depending on pain severity with acetaminophen or NSAIDs [A] COX-2 inhibitors and muscle relaxants have not been shown to be more effective than NSAIDs [A]. Opiate analgesics have not been shown to be more effective than NSAIDs in acute low back pain. <p>Testing:</p> <ul style="list-style-type: none"> Diagnostic tests or imaging usually not required. If no improvement after 6 weeks, consider imaging.
	Assessment to identify potential serious pathology	<p>Assess for "red flag" indications of serious disease:</p> <ul style="list-style-type: none"> Cauda Equina Severe or progressive neurologic deficit Recent bowel or bladder dysfunction Saddle anesthesia <p>Cancer</p> <ul style="list-style-type: none"> Men and women age > 50 Cancer history Insidious onset No relief at bedtime or worsening when supine Constitutional symptoms (e.g. fever, weight loss) Male with diffuse osteoporosis or compression fracture Cauda Equina syndrome or severe or progressive neurologic deficit — Refer for emergency studies and definitive care [C] Spinal fracture or compressions — Plain LS spine X-ray [B]. After 10 days, if fracture still suspected or multiple sites of pain, consider either bone scan [C] or referral [D] before considering CT or MRI. Cancer or infection — CBC, urinalysis, ESR [C]. If still suspicious consider referral or seek further evidence (e.g. bone scan [C], other labs — negative plain film X-ray does not rule out disease).
	Patients with high risk of serious pathology (red flags)	<p>Fracture</p> <ul style="list-style-type: none"> Traumatic injury or onset, cumulative trauma Steroid use history Women age > 50 <p>Infection</p> <ul style="list-style-type: none"> Steroid use history Diabetes Mellitus Immune suppression History UTI or other infection Constitutional symptoms (e.g. fever, weight loss) No relief at bedtime or worsening when supine <ul style="list-style-type: none"> HIV Previous surgery Insidious onset IV drug use

Levels of Evidence for the most significant recommendations: A = randomized controlled trials; B = controlled trials, no randomization; C = observational studies; D = opinion of expert panel
 This guideline lists core management steps. It is based on several sources, including the ICSI Adult Low Back Pain Guideline, Institute for Clinical Systems Improvement, 2006 (www.icsi.org). Individual patient considerations and advances in medical science may supersede or modify these recommendations.
 Approved by MQIC Medical Directors 03/08 www.mqic.org



Michigan Quality Improvement Consortium Guideline Management and Prevention of Osteoporosis

The following guideline recommends assessment and management of patients with osteopenia and osteoporosis.

Eligible Population	Key Components	Recommendation and Level of Evidence	Frequency
Patients at potential risk for osteoporosis	Assessment	<ul style="list-style-type: none"> ■ Assess for loss of height (> 1.5 inches) and back pain. ■ Assess other risk factors: <ul style="list-style-type: none"> • Current cigarette smoking • Low body weight (<127 lbs or BMI < 20) • Female gender • Menopause • Endocrine disorders: <ul style="list-style-type: none"> • Premature or surgical menopause • Chronic corticosteroid therapy • Estrogen or testosterone deficiency • Excessive thyroid hormone replacement • Calcium or vitamin D deficiency • Depo-Provera use ■ Bone mineral density (BMD) testing using DEXA for high risk patients or moderate risk patients at risk for falls. ■ CT scan for screening is not recommended. 	<ul style="list-style-type: none"> • Adult height assessments at periodic well exams
Patients requiring therapy to reduce high risk of fracture	Core Principles of Treatment and Prevention	<ul style="list-style-type: none"> ■ Regardless of risk factors: <ul style="list-style-type: none"> • Dietary calcium 1200 mg/d and 800 - 1000 IU vitamin D₃ [B] • Weight-bearing exercise [A] • Address modifiable risk factors above 	<ul style="list-style-type: none"> • BMD testing more often than every two years is generally not useful. • Consider rechecking BMD after at least two years of pharmacologic treatment to monitor effectiveness. [D]
Patients requiring therapy to reduce high risk of fracture	Patient Selection for Pharmacological Management Based on DEXA	<ul style="list-style-type: none"> • Treatment to prevent fractures in osteopenia [T-score between -1 and -2.0] without risk factors is not useful. [D] • Treat patients on corticosteroid therapy with a T-score \leq -1.0. [A] • Treat patients with osteopenia and a T-score between -2.0 and -2.5 at increased risk. [D] • Patients with osteoporosis [T-score < -2.5] (Osteopenia associated with atraumatic fracture should be treated as osteoporosis [D]). 	
Patients requiring therapy to reduce high risk of fracture	Pharmacological Management	<ul style="list-style-type: none"> • Consider oral bisphosphonate, generic, if available. • Consider referral to endocrine or bone and mineral metabolism specialist if patient does not tolerate treatment or shows progression or recurrent fracture after 2 years on treatment. 	

¹ Use caution in patients with active upper GI disorders. Take medication on an empty stomach with water, remain upright, no food or beverage for 30 minutes. (60 minutes for ibandronate).

Levels of Evidence for the most significant recommendations: A = randomized controlled trials; B = controlled trials, no randomization; C = observational studies; D = opinion of expert panel. This guideline represents core management steps. It is based on The Guide to Clinical Preventive Services 2007, Recommendations of the U.S. Preventive Services Task Force (www.preventiveservices.hhs.gov) and the Diagnosis and Treatment of Osteoporosis Guideline, Institute for Clinical Systems Improvement, 2008 (www.icsi.org). Individual patient considerations and advances in medical science may supersede or modify these recommendations.

Michigan Quality Improvement Consortium Guideline Acute Pharyngitis in Children

The following guideline recommends assessment, diagnosis and treatment interventions for the management of acute pharyngitis in children and adolescents.

Eligible Population	Key Components	Recommendation and Level of Evidence
Children 2-18 years old with suspected GABHS pharyngitis	Assessment	<p>Assess past history of rheumatic fever (especially carditis or valvular disease) or household contact with a history of rheumatic fever to identify high-risk patients.</p> <p>Assess the likelihood of strep pharyngitis by looking for the following:</p> <ul style="list-style-type: none"> • Sudden onset • Headache • Nausea, vomiting and abdominal pain • Inflammation of pharynx and tonsils • Fever • Tender, enlarged anterior cervical nodes • Patchy discrete exudate • No cough <p>• Patient 5-15 years old</p> <p>• Presentation in winter or early spring</p> <p>• History of exposure</p>
Not high-risk for rheumatic fever	Diagnosis	<p>Testing (intermediate or high probability of GABHS):</p> <p>Throat culture</p> <p>Or</p> <p>Rapid screen</p> <p>• If throat culture is positive, use antibiotics.</p> <p>• If throat culture is negative, use symptomatic treatment only. Avoid antibiotics.</p>
High-risk for rheumatic fever or household contact with history of rheumatic fever or confirmed strep	Treatment	<p>Start antibiotics immediately. Obtain throat culture. If negative, stop antibiotics.</p> <p>• If rapid screen is positive, use antibiotics.</p> <p>• If rapid screen is negative, culture¹ and only use antibiotics if throat culture is positive.</p> <p>• See www.med.umich.edu/1info/FHP/practiceguides/pharyngitis/pharyn.pdf for detailed drug and dosing recommendations.</p> <p>Preferred Treatment for Strep Pharyngitis:</p> <ol style="list-style-type: none"> 1) Penicillin VK: 250-500 mg bid-tid x 10 days 2) Amoxicillin: 40 mg/kg/d divided bid-tid x 10 days [A] or 750 mg daily x 10 days if compliance is a concern 3) Benzathine penicillin G IM x1 4) If allergic to penicillin: erythromycin ethyl succinate: 40 mg/kg/day bid-qid (max 1 gm/day) x 10 days or azithromycin 5) With oral antibiotics, a full 10-day course is required (exception: azithromycin). 6) Cephalosporins <p>Alternative Treatment for Strep Pharyngitis:</p> <ol style="list-style-type: none"> 1) If failure to respond clinically after 48 hours of treatment, rule out peritonsillar or retropharyngeal abscess. If present, prompt ENT evaluation is recommended. 2) Assess the potential for a compliance problem.
	Re-evaluation, referral	
	Culture optional for age 16 and older	

¹ Culture optional for age 16 and older

Levels of Evidence for the most significant recommendations: A = randomized controlled trials; B = controlled trials, no randomization; C = observational studies; D = opinion of expert panel

This guideline lists core management steps. It is based on several sources including the ICSI Diagnosis and Treatment of Respiratory Illness in Children and Adults Guideline, Institute for Clinical Systems Improvement, 2008 (www.icsi.org). Individual patient considerations and advances in medical science may supersede or modify these recommendations.

Management of Uncomplicated Acute Bronchitis in Adults

The following guideline recommends assessment, diagnosis, treatment and counseling interventions for the management of uncomplicated acute bronchitis in adults.

Eligible Population	Key Components	Recommendation and Level of Evidence
Adults 18 years or older with clinical suspicion of uncomplicated acute bronchitis	Assessment	<ul style="list-style-type: none"> • Perform thorough history (including tobacco use status [A]) and physical exam • Assess the likelihood of uncomplicated acute bronchitis using the following items: <ul style="list-style-type: none"> - Acute respiratory infection (ARI) manifested predominantly by cough, with or without sputum production lasting no more than 3 weeks - No clinical evidence of pneumonia - Common cold, acute asthma, or exacerbation of COPD have been ruled out as cause of cough - Consider other diagnoses if cough persists greater than 3 weeks
	Diagnosis	<p>Clinical Information and Testing:</p> <ul style="list-style-type: none"> • Presumed diagnosis of acute bronchitis: <ul style="list-style-type: none"> - ARI and cough with or without sputum production lasting no more than 3 weeks - No clinical evidence of pneumonia • Viral cultures, serologic assays and sputum analyses should not be routinely performed [C] • Chest x-ray is not indicated if all of the following are present [B]: <ul style="list-style-type: none"> - Acute cough and sputum production suggestive of acute bronchitis - Heart rate < 100 beats/min - Respiratory rate < 24 breaths/min - Oral temperature < 38° C (100.4° F) - Chest exam lacks findings of focal consolidation, egophony or fremitus
	Treatment	<ul style="list-style-type: none"> • Condition is a self-limited respiratory disorder. Symptomatic treatment only. Routine treatment with antibiotics is not justified and should not be offered. Avoid antibiotics [A] • Beta₂-agonist bronchodilators should not be routinely used to alleviate cough. In select patients with wheezing, treatment with beta₂-agonists bronchodilators may be useful [C] • Antitussive agents can be offered for short-term symptomatic relief of coughing [C] • Mucokinetic (mucolytic) agents are not recommended (no consistent favorable effect) [D]
	Education and counseling	<p>Educate patient/family regarding:</p> <ul style="list-style-type: none"> • Condition often does not require medical treatment • Inform patient that cough may last for 3 weeks • Routine use of antibiotics is not recommended [A] • Use the term "chest cold" which is associated with less patient belief that antibiotics are needed • Rest and increasing fluid intake • Smoking cessation and second-hand smoke avoidance [C] (See also <i>MOIC Tobacco Control Guideline</i>)

Levels of Evidence for the most significant recommendations: A = randomized controlled trials; B = controlled trials, no randomization; C = observational studies; D = opinion of expert panel

This guideline lists core management steps. It is based on several sources including the American College of Chest Physicians Chronic Cough Due to Acute Bronchitis: ACCP Evidence-Based Clinical Practice Guidelines, 2008 (www.chestjournal.org). Individual patient considerations and advances in medical science

A	
A-200	41
ABILIFY	7
Acarbose	17
ACCOLATE	26
ACCUPRIL	21
ACCURETIC	21
Acetaminophen	31
Acetaminophen/codeine	32
Acetazolamide	22
Acetic Acid	38
Acetic Acid/Oxquin	29
Acetylcysteine	42
ACI-JEL	29
ACTIFED	24
ACTIMMUNE	5
ACTOPLUS	17
ACTOS	17
ACULAR	36
ACULAR LS	36
Acyclovir	14, 42
ADALAT-CC	20
ADDERALL	7
ADDERALL, XR	7
ADVAIR	26
ADVATE	5
AEROCHAMBER, & MASK	27
AGENERASE	7
AGGRENOX	36
AK-DEX SOLN	36
AKINETON	7, 34
AK-TRACIN	37
Albuterol	25
ALDACTAZIDE	22
ALDACTONE	22
ALDOMET	22
Alendronate	18
ALESSE	16
Alfuzosin	30
ALINIA	15
ALKERAN	6
ALLEGRA	24
ALLEGRA-D	24
Allopurinol	33
ALOCRIAL	36
ALOMIDE	36
ALPHAGAN P	36
ALPHANATE	5
ALPHANINE	5
Altrefamine	6
Aluminum Chloride	41
ALUPENT	25
Amantadine	14
Amantadine HCL	34
AMARYL	17
AMBIEN CR	7
Amino Acid/Urea Cervical Cream ...	30
AMINO-CERV	30
Amiodarone	20
AMITIZA	29
Amlodipine	20
Amoxicillin	12
Amoxicillin/potassium clavulanate ...	12
Ampicillin	12
ANAFRANIL	7
ANA-GUARD	42
ANA-KIT	42
ANAPROX	32
ANAPROX DS	32
Anastrozole	6
Antacid Liquid	28
Anthralin	41
ANTIVERT	28
ANUSOL HC SUPP	41
APAP/ASA/Caffeine	33
APLENZIN, ER	7
APLIGRAF	5
APRESOLINE	22
APRISO	29
APTIVUS	7
ARICEPT	30
ARIMIDEX	6
ARANESP	5
ARIXTRA	5
ARMOUR THYROID	18
ARTANE	7
ARTHROTEC	33
ARTIFICIAL TEARS	38
ASACOL	29
ASENDIN	7
ASPIRIN	31, 36
Aspirin / Codeine	31
ASTEPRO	23
ATARAX	23
Atenolol	20
Atenolol/Chlorthalidone	19
ATIVAN	7
ATRIPLA	7
Atropine	38
ATROVENT INHALER	27

Attapulgit.....	27	Bisoprolol / HCTZ.....	20
Augmented betamethasone dipropionate.....	41	BLEPH 10.....	37
AUGMENTIN.....	12	BLEPHAMIDE.....	37
AURALGAN.....	39	BRETHINE.....	25
AUTOPLEX.....	5	Brimonidine.....	36
AVELOX.....	14	BROMFED, -PD.....	24
AVONEX.....	5	Bromocriptine.....	18, 34
AYGESTIN.....	16	Bromphen/Decong.....	24
Azathioprine.....	6	Brompheniramine/ Pseudoephedrine.....	24
Azelastine.....	23	BRONCHO SALINE.....	27
Azithromycin.....	13	Budesonide.....	26
AZULFIDINE.....	29	Budesonide/Formoterol.....	26
B		Bumetanide.....	22
Bacitracin.....	37	BUMEX.....	22
Bacitracin ointment.....	39	Bupropion SR.....	31
Baclofen.....	34	BUSPAR, VANSPAR.....	7
BACTRIM.....	14	Busulfan.....	6
BACTROBAN.....	41	Butalbital/APAP/Caffeine.....	31
BANZEL.....	7	Butalbital/APAP/Caffeine/ Codeine.....	31
BARACLUDE.....	15	Butalbital/ASA/Caffeine.....	31
Barium Enema Prep Kit.....	42	Butalbital/ASA/Caffeine/ Codeine.....	31
BEBULIN.....	5	BUTISOL SODIUM.....	7
Beclomethasone.....	26	C	
Belladonna alkaloids/ phenobarbital.....	29	CAFERGOT.....	33
BENADRYL.....	23	Caffeine Citrate.....	42
BENADRYL SYRUP.....	23	CAFFEINE CITRATE SOLUTION.....	42
Benazepril.....	21	Calamine Lotion.....	41
Benazepril/HCTZ.....	21	CALAN.....	20
BENEFIX.....	5	CALAN SR.....	20
BENICAR.....	21	CALCIFEROL.....	18
BENICAR HCT.....	21	Calcipotriene.....	41
BENTYL.....	29	Calcitonin Salmon.....	18
Benzocaine/antipyrine.....	39	Calcitrol.....	35
Benzonate.....	25	Calcium Acetate.....	42
Benzoyl peroxide.....	39	Calcium carbonate.....	28, 35
BETAGAN.....	37	CAMPREL.....	7
Betamethasone.....	40	CAPOTEN.....	21
Betamethasone valerate.....	40	CAPOZIDE.....	21
Betaxolol.....	37	Captopril.....	21
Bethanechol.....	30	Captopril/HCTZ.....	21
BETOPTIC.....	37	CARAFATE.....	28
BIAXIN+.....	13	Carbamide peroxide.....	39
Bicalutamide.....	6	CARBATROL.....	7
Biperiden HCL.....	34	Carbidopa/levodopa.....	34
Bisacodyl.....	29	Carbinoxamine/phenylephrine.....	24
Bismuth Subsalicylate.....	27		
Bisoprolol.....	20		

CARDIZEM, -CD, -SR	20	Ciprofloxacin.....	14
CARDURA.....	22, 30	Ciprofloxacin/Dexamethasone	38
Carisoprodol	34	Clarithromycin.....	13
Carisoprodol/ASA.....	34	CLARITIN OTC.....	24
CARNITOR.....	35	CLARITIN SYRUP	24
Carvedilol.....	19	CLARITIN-D OTC.....	24
CASODEX.....	6	Clemastine.....	24
CATAPRES	22	CLEOCIN.....	15
CDZ/Clidinium	29	CLEOCIN VAG CREAM.....	29
CECLOR.....	12	CLEOCIN-T.....	39
CECLOR CD.....	12	Clindamycin.....	15, 29, 39
CEENU	6	CLINORIL.....	32
Cefaclor	12	Clonidine.....	22
Cefadroxil Monohydrate	12	Clopidogrel.....	36
Cefdinir.....	12	Clotrimazole.....	14, 29, 39
Cefixime	12	Clotrimazole/-	
Cefprozil.....	12	betamethasone	40
CEFTIN.....	12	Clotrimazole-cream/solution.....	40
Cefuroxime.....	12	CLOZARIL.....	7
CEFZIL.....	12	Codeine/phenylephrine/	
CELEXA	7	promethazine	25
CELLCEPT	6	Codeine/promethazine.....	25
CELONTIN	7	COGENTIN	7
Cephalexin.....	12	CONCERTA.....	7
CEPHULAC	29	COLACE.....	29
CEREBYX.....	7	COLESTID TABLETS.....	23
Ceririzine.....	24	Colestipol	23
CERON.....	24	COLYTE	29
Cetirizine.....	24	COLYTE FLAVORED	29
Cetirizine/Pseudoephedrine.....	24	COMBIVENT	27
CHANTIX.....	31	COMBIVIR.....	7
Chewable Prenatal Vitamin.....	34	COMPAZINE.....	28
Childrens Chewable Vitamin	35	CONCERTA.....	7
CHILDRENS Chewable		Condoms	42
Vitamin w/iron.....	35	CONDYLOX	41
Chlorambucil	6	CONTAC.....	24
Chloramphenicol.....	38	COPAXONE.....	5
Chlorhexidine Gluconate	42	COPEGUS	5
CHLOROMYCETIN	38	CORDARONE	20
Chlorpheniramine	24	COREG.....	19
Chlorpheniramine/		CORGARD.....	20
Pseudoephedrine.....	24	CORTEF.....	15
Chlorpropamide	17	CORTISPORIN.....	37
CHLOR-TRIMETON.....	24	CORTISPORIN OTIC.....	38
Chlortrimeton/Decong.....	24	COSOPT.....	38
Cholestyramine.....	23	COUMADIN	9, 35
Ciclopirox.....	40	COZAAR.....	21
Cimetidine.....	28	CREON.....	29
CIPRO	14	CRESTOR.....	23
CIPRODEX	38	CRIXIVAN	7

Cromolyn	27	Dicloxacillin	12
CROMOLYN NEBULIZER		Dicyclomine	29
SOLUTION	27	Diflorasone diacetate	41
Cromolyn sodium.....	36	DIFLUCAN	14, 29
Cromolyn-Nasal inhaler.....	24	DIGITEK	9, 19
Cyclobenzaprine	34	Digoxin.....	9, 19
CYCLOGYL.....	38	Digoxin Solution.....	19
Cyclopentolate.....	38	DIGOXIN SOLUTION.....	19
Cyclophosphamide	6	Dihydroergotamine	33
Cyclosporine	6, 9	DILACOR XR	20
CYCRIN.....	16	DILANTIN	7
CYMBALTA.....	7	DILATRATE SR.....	19
Cyproheptadine	24	DILAUDID.....	31
CYTOTEC	28	Diltiazem & Diltiazem ER.....	20
CYTOXAN.....	6	DIMETAPP	24
D		Diphenhydramine.....	23
DALMANE.....	7	Diphenoxylate/atropine.....	27
Danazol.....	18	Dipivefrin	38
DANOCRINE	18	DIPROLENE	41
DARAPRIM	15	DIPROLENE AF	40
DAYPRO	33	DIPROSONE	40
DAYTRANA	7	Dipyridamole/ASA	36
DDAVP	5	DISALCID	31
DEBROX.....	39	DITROPAN	30
DECADRON.....	15, 36	DITROPAN XL	30
DECONAMINE SR	24	Docusate sodium	29
DEPAKENE.....	7	Docusate/casanthrol	29
DEPAKOTE, -ER.....	7	Donepezil	30
DEPONIT.....	19	DONNATAL.....	29
DEPO-PROVERA.....	16	DORAL.....	7
DERMATOP.....	40	Dorzolamide HCL	37
Desonide.....	40	Dorzolamide/Timolol.....	38
Desoximetasone	40, 41	DOVONEX.....	41
DESQUAM-E.....	39	Doxazosin	22, 30
DESQUAM-X	39	Doxycycline	13
DESYREL	7	DRISDOL.....	34
DETROL LA.....	30	DRITHOCREME.....	41
Dexamethasone.....	15, 36	Dronedarone	20
DEXEDRINE.....	7	DRYSOL	41
Dextromethorphan/ promethazine	25	DULCOLAX.....	29
DEXTROSTAT	7	DURICEF	12
DIABETA.....	17	DYAZIDE	22
DIABINESE.....	17	DYNACIRC	20
DIAMOX.....	22	DYNACIRC CR.....	20
Diaphragm	42	DYNAPEN.....	12
DIASTAT, ACUDIAL.....	7	E	
Diclofenac.....	32, 36	EASIVENT	27
Diclofenac/Misoprostol.....	33	EDLUAR	7
		EES.....	13

EFFEXOR, -XR.....	7	EUFLEXXA.....	5
EFUDEX.....	41	EULEXIN.....	6
ELAPRASE.....	5	EVISTA.....	18
ELAVIL.....	7	EXCEDRIN MIGRAINE.....	33
ELDEPRYL.....	34	EXELON.....	30
Eletriptan Hydrobromide.....	33	EXTAVIA.....	5
ELIDEL.....	41	Ezetimibe / Simvastatin.....	23
ELIMITE.....	41		
ELOCON.....	40	F	
EMSAM.....	7	Famotidine.....	28
EMCYT.....	6	FARESTON.....	6
EMTRIVA.....	7	FAZACLO.....	7
Enalapril.....	21	FEIBA-VH.....	5
Enalapril / HCTZ.....	21	FELBATOL.....	7
ENBREL.....	5	FELDENE.....	32
Enoxaparin.....	35	FEMARA.....	6
Entecavir.....	15	FEMHRT.....	16
EPIFOAM.....	41	FENESIN DM.....	25
EPIVIR.....	7	Fenofibrate.....	23
EPOGEN.....	5	FEOSOL.....	35
EPZICOM.....	7	FERGON.....	35
ERGAMISOL.....	6	Ferrous Gluconate.....	35
Ergocalciferol.....	18	Ferrous Sulfate.....	35
Ergotamine/caffeine.....	33	Fexofenadine.....	24
ERYCETTE.....	39	Fexofenadine/Pseudoephedrine.....	24
ERY-TAB.....	13	FIORICET.....	31
ERYTHROCIN.....	13	FIORICET W/CODEINE.....	31
Erythromycin.....	37, 39	FIORINAL.....	31
Erythromycin base.....	13	FIORINAL W/CODEINE.....	31
Erythromycin ethylsuccinate.....	13	FLAGYL.....	15
Erythromycin stearate.....	13	FLEETS PREP KIT.....	42
ESTRACE.....	15	FLEXERIL 10MG.....	34
ESTRADERM PATCH.....	16	FLONASE.....	23, 39
Estradiol.....	15	FLORINEF.....	15
Estradiol Transdermal.....	16	FLORONE.....	41
Estramustine.....	6	FLORONE E.....	41
Estrogen/Progesterone.....	16	FLOXIN.....	14
Estrogens, conjugated.....	15	FLOXIN OTIC.....	38
ESTROSTEP.....	16	Fluconazole.....	14
Ethambutol.....	14	Fluconazole Tablet.....	29
Ethinyl estradiol/desogestrel.....	16	Fludrocortisone.....	15
Ethinyl estradiol/Drosirenone.....	16	Fluocinolone acetonide.....	40
Ethinyl estradiol/norethindrone... ..	16	Fluocinonide.....	40
Ethinyl estradiol/ norethindrone acetate.....	16	Fluorometholone.....	36
Ethinyl estradiol/norgestimate.....	16	Fluoruracil, topical.....	41
Etodolac.....	32	Flurbiprofen.....	36
Etonogestrel/ethinyl estradiol.....	16	Flutamide.....	6
Etoposide.....	6	Fluticasone.....	23, 39
ETRAFON.....	7	Fluticasone/Salmeterol.....	26
		FML.....	36

FML FORTE.....	36
FML S.O.P.....	36
FOCALIN, XR.....	7
Folic acid.....	35
Folic acid/B-12/Iron	35
Fomoterol.....	25
FORADIL	25
FORTEO.....	5
FORTOVASE	7
FOSAMAX	18
FRAGMIN	5
FULVICIN PG.....	14
FULVICIN UF.....	14
Furosemide.....	22
Furosemide Solution	22
FUZEON	7

G

GABITRIL	7
Galatamine	30
GANTRISIN.....	14
GARAMYCIN	39
Gatifloxacin	37
Gemfibrozil	23
GENOPTIC.....	37
Gentamicin.....	37, 39
GLEEVEC.....	5
Glimepiride	17
Glipizide	17
Glipizide extended release	17
Glucagon	18
GLUCAGON KIT	18
Glucometer.....	17
GLUCOPHAGE	17
GLUCOPHAGE XR.....	17
Glucose Test Strips.....	17
GLUCOTROL	17
GLUCOTROL XL	17
GLUCOVANCE	17
Glyburide.....	17
GLYNASE.....	17
GEODON.....	7
Gramicidin/neomycin/ polymyxin B	37
Griseofulvin.....	14
Guaifenesin.....	25
Guaifenesin/Codeine	25
Guaifenesin/ Dextromethorphan.....	25

Guaifenesin/Pseudoephedrine/ Codeine.....	25
GYNE-LOTRIMIN	30

H

Halcinonide.....	40
HALCION	7
HALDOL.....	7
Halobetasol.....	40
HALOG	40
HALOG-E.....	40
HELIXATE.....	5
HERCEPTIN	5
Hexachlorophene.....	42
HEXALEN	6
HISTUSSIN HC.....	24
HIVID.....	7
Homatropine.....	38
HUMALOG.....	17
HUMATE P	5
HUMATROPE.....	5
HUMIBID DM	25
HUMIBID LA	25
HUMIRA	5
HUMULIN.....	17
HUMULIN PENS.....	17
Hydralazine	22
HYDREA	6
Hydrochlorothiazide.....	22
Hydrocodone Bitartrate/APAP	32
Hydrocodone/Acetaminophen	31, 32
Hydrocodone/Phenyl/CTM	24
Hydrocort./acetic acid	39
Hydrocortisone	15, 40, 41
Hydrocortisone Acetate	41
Hydrocortisone valerate	40
Hydrocortisone/neo/ polymyxin B	38
Hydrocortisone/neomycin/ polymyxin B.....	37
Hydrocortisone/pramoxine.....	41
HYDRODIURIL	22
Hydromorphone.....	31
Hydroxychloroquine.....	33
Hydroxyurea.....	6
Hydroxyzine	23
Hyoscyamine sulfate	29
HYTONE.....	40
HYTRIN	22, 30
HYZAAR	21

I	
Ibuprofen.....	32
ILOTYCIN OPTH OINT	37
IMDUR.....	19
IMITREX.....	33
IMODIUM.....	27
IMURAN	6
INAPSINE	7
INCRELEX	5
Indapamide	22
INDERAL.....	20
INDOCIN	32, 33
Indomethacin.....	32, 33
INFERGEN.....	5
Inhaler enhancement device	27
INNOPRAN XL.....	20
Insect Sting Kit.....	42
Insulin Glargine	17
Insulin Lispro.....	17
Insulin Syringes.....	17
Insulin-Human, recombin	17
INTRON A	5
INTUNIV	7
INVIRASE	7
Ipratropium.....	27
Ipratropium / Albuterol.....	27
ISMO	19
Isometheptene/ dichloralphenazone/ APAP	33
Isoniazid	14
ISONIAZID.....	14
ISOPTO ATROPINE.....	38
ISOPTO HOMATROPINE.....	38
ISOPTO HYOSCINE.....	38
ISORDIL.....	19
Isosorbide dinitrate.....	19
Isosorbide dinitrate SR.....	19
Isosorbide mononitrate.....	19
Isradipine.....	20
J	
JANUMET.....	17
JANUVIA	17
K	
KADIAN.....	32
KALETRA.....	7
KAOPLECTATE	27
KAYEXALATE.....	42
K-DUR 20.....	35
K-DUR-10	35
KEFLEX.....	12
KEMADRIN.....	7
KENALOG	40
KEPPRA, XR	7
KETEK.....	13
Ketoconazole	14
Ketoprofen CR Capsules.....	33
Ketoralac tromethamine.....	33
Ketorolac	36
Ketotifen	36
KLONOPIN	7
KLOTRIX	35
K-LYTE/Cl.....	35
KOATE.....	5
KOGENATE.....	5
KOMBIGLYZE XR	17
K-TABS.....	35
KWELL	41
L	
Labetalol.....	20
Lactulose.....	29
LAMICTAL, ODT, XR.....	7
LAMISIL TABLETS	14
Lancets.....	17
LANOXIN	9, 19
Lansoprazole	28
LANTUS.....	17
LANTUS SOLOSTAR.....	17
LASIX	22
LASIX SOLUTION	22
Latanoprost	38
Letrozole	6
LEUKERAN.....	6
LEUKINE	5
Levamisole	6
LEVAQUIN	14
LEVATOL.....	20
LEVLEN.....	16
Levobunolol	37
Levocarnitine	35
Levofloxacin	14
Levonorgestrel/ ethinyl estradiol.....	16
Levothyroxine	9, 18
LEVOXYL	9, 18
LEVSIN.....	29
LEVSINEX.....	29
LEXAPRO.....	7

LEXIVA.....	7	MACRODANTIN	15
LIBRAX	29	MARPLAN	7
LIBRIUM.....	7	MATULANE.....	6
LIDEX.....	40	MAVIK.....	21
Lidocaine	42	MAXAIR AUTOHALER.....	25
Lidocaine viscous.....	39	MAXZIDE	22
Lidocaine/Prilocainc.....	41	MEBARAL.....	7
LIMBITROL, DS.....	7	Mebendazole	15
Lindane lotion, shampoo	41	Meclizine	28
LIORESAL.....	34	MEDROL	15
Lipase/protease/amylase	29	Medroxyprogesterone.....	16
Lisinopril	21	Medroxyprogesterone	
Lisinopril /HCTZ.....	21	acetate	16
LO OVRAL.....	16	MEGACE	6
LODINE, -XL.....	32	Megestrol	6
Lodoxamide.....	36	MELLARIL	7
LOESTRIN	16	Meloxicam.....	32
LOFIBRA	23	Melphalan.....	6
LOMOTIL	27	Memantine	30
Lomustine.....	6	MEPHYTON.....	34
Loperamide HCl.....	27	Mercaptoprine.....	6
LOPID.....	23	Mesalamine	29
LOPRESSOR	19	MESTINON	34
LOPROX	40	METADATE ER, CD.....	7
Loratadine	24	METAMUCIL POWDER.....	29
Loratadine/pseudoeph.....	24	Metformin	17
LORCET	31	Metformin / Glipizide	17
LORTAB	32	Metformin,	
Losartan.....	21	Extended-Release	17
Losartan/HCTZ	21	METHADONE	32
LOTENSIN	21	Methadose	32
LOTENSIN - HCT.....	21	Methazolamide	22
LOTRISONE	40	METHERGINE	42
LOVENOX.....	5, 35	Methimazole.....	18
LOXITANE.....	7	Methocarbamol.....	34
LOZOL	22	Methotrexate	6, 33
Lubiprostone	29	METHOTREXATE	33
LUCENTIS	5	Methyldopa	22
LUDIOMIL	7	Methylergonovine.....	42
LUMINAL	7	Methylprednisolone.....	15
LUNESTA	7	Metoclopramide.....	29
LUPRON	5	Metolazone	22
LURIDE	35	Metoprolol.....	19
LUVOX, CR	7	Metoprolol ER.....	20
LYRICA.....	7	Metronidazole	15, 30
LYSODREN	6	MIACALCIN	
		NASAL SPRAY	18
M		Miconazole	29
MAALOX/MAALOX TC	28	MICROCHAMBER.....	27
MACROBID.....	15	MICRONOR.....	16

MIDRIN	33
MIGRANAL NASAL SPRAY	33
MILTOWN	7
MINIPRESS.....	22
MIRALAX POWDER	29
Misoprostol	28
Mitotane	6
MOBAN.....	7
MOBIC.....	32
MODICON	16
Momentasone furoate	40
Mometasone.....	39
MONARCH M	5
MONCLATE.....	5
MONISTAT	29
MONOGESIC.....	31
MONOKET	19
MONONINE	5
Montelukast	26
Morphine sulfate CR	32
Morphine sulfate IR.....	32
MOTRIN	32
Moxifloxacin	14
MS CONTIN.....	32
MSIR.....	32
MUCOMYST	42
MULTAQ	20
Multi-Vitamin.....	35
Multi-Vitamin w/ iron.....	35
Multi-Vitamin w/fluoride & iron.....	35
Multi-vitamins & fluoride.....	34, 35
Mupirocin.....	41
MYAMBUTOL.....	14
MYCELEX	14, 39
MYCELEX TROCHE.....	39
MYCELEX-G.....	30
MYCOLOG II.....	40
Mycophenolate Mofetil.....	6
MYCOSTATIN	30, 39, 40
MYCOSTATIN POWDER.....	41
MYDRIACYL.....	38
MYLANTA/ II	28
MYLERAN	6
MYLICON.....	28
MYOBLOC	5
MYSOLINE	7

N

Nabumentone	33
Nadolol.....	20
Nafarelin.....	18
NAMENDA	30
Naphazoline/Antazoline.....	36
NAPROSYN	32
Naproxen	32
Naproxen Sodium.....	32
NARDIL.....	7
NASALCROM.....	24
NASONEX.....	39
NATACHEW	34
NATACYN	37
NATALINS RX	34
Natamycin 5%.....	37
NAVANE.....	7
Nedrocromil.....	36
Neomycin	14
NEORAL.....	6, 9
NEOSPORIN	37
NEOSYNEPHRINE.....	38
NEPTAZANE	22
NEULASTA	5
NEUMEGA	5
NEUPOGEN	5
NEURONTIN	7
NEXAVAR.....	5
NIACIN	23
Niacin, Niacin SR.....	23
NIASPAN	23
NICORETTE GUM.....	31
Nicotine Inhaler	31
Nicotine Nasal Spray.....	31
Nicotine polacrilex.....	31
Nicotine transdermal.....	31
NICOTROL INHALER.....	31
NICOTROL PATCH	31
NICOTROL SPRAY	31
Nifedipine.....	20
Nifedipine SR.....	20
NIFEREX PN	34
NIFEREX-150 FORTE.....	35
NIRAVAM	7
Nitazoxanide	15
NITRO-BID	19
NITRO-DUR.....	19
Nitrofurantoin	15
Nitrofurantoin monohyd/ macrocrystals LA.....	15

Nitroglycerin	19	Ondansetron	28
Nitroglycerin Oint	19	ONGLYZA.....	17
Nitroglycerin patch.....	19	OPTICROM.....	36
Nitroglycerin spray	19	ORAMORPH SR	32
Nitroglycerin SR.....	19	ORAP	7
NITROL OINT	19	ORAPRED.....	15
NITROLINGUAL SPRAY.....	19	ORASONE.....	15
NITROSTAT.....	19	ORINASE	17
NIX-OTC.....	41	Orphenadrine/ASA/ Caffeine.....	34
NIZORAL.....	14	ORTHO TRI-CYCLEN	16
NOLVADEX.....	6	ORTHO-CEPT.....	16
NORCO.....	32	ORTHO-CYCLEN	16
NORDETTE.....	16	ORTHO-NOVUM 1/35	16
Norethindrone	16	ORTHO-NOVUM 1/50	16
Norethindrone acetate.....	16	ORTHO-NOVUM 10/11	16
Norethindrone ethinyl estradiol.....	16	ORTHO-NOVUM 7/7/7	16
Norethindrone/mestranol.....	16	ORUVAIL	33
NORGESIC	34	OS-CAL	35
NORGESIC FORTE.....	34	OVCON-35	16
Norgestimate/ ethinyl estradiol.....	16	OVCON-50	16
Norgestrel.....	16	OVRAL	16
Norgestrel/ethinyl estradiol.....	16	OVRETTE	16
NORMODYNE.....	20	Oxaprozin.....	33
NORPRAMIN.....	7	Oxybutynin	30
NORVASC.....	20	Oxybutynin XL	30
NOVANTRONE.....	5	Oxycodone/APAP	32
NORVIR	7	Oxycodone/ASA.....	32
NOVOLIN	17	P	
NOVOLOG	17	PACERON	20
NOVOLOG PENS.....	17	PAMELOR.....	7
NOVOSEVEN	5	Pantoprazole.....	28
NOXAFIL	14	PARAPECTOLIN.....	27
NUVA RING	16	PARLODEL	18, 34
NUVIGIL.....	7	PARNATE	7
Nystatin	30, 40, 41	PATADAY.....	36
Nystatin suspension.....	39	PATANOL.....	36
O		PAXIL, CR	7
OCETREOTIDE.....	5	Ped. Electrolyte Solution	35
OCUFEN.....	36	PEDIALYTE	35
OCUFLOX.....	37	PEDIAZOLE.....	14
Ofloxacin	14, 37, 38	PEGANONE.....	7
Olmesartan.....	21	PEGASYS	5
Olmesartan / HCTZ	21	PEG-INTRON.....	5
Olopatadine.....	36	PEG Solution.....	29
OMEPRAZOLE	28	Penbutolol.....	20
Omeprazole caps.....	28	Penicillin VK	12
OMNICEF.....	12	Pentoxifylline.....	23
		PEPCID AC	28

PEPTO BISMOL.....	27	PRED FORTE.....	36
PERCOCET.....	32	PRED MILD.....	36
PERCODAN.....	32	PRED-G DROPS.....	37
PERIACTIN.....	24	PRED-G S.O.P. OINT.....	37
PERI-COLACE.....	29	Prednicarbate.....	40
PERIDEX.....	42	Prednisolone.....	15, 36
Permethrin.....	41	PREDNISOLONE.....	15
PEXEVA.....	7	Prednisolone acetate/ neomycin/ polymixin B.....	37
Phenazopyridine.....	30	Prednisolone acetate/ gentamicin.....	37
PHENERGAN.....	28	Prednisolone acetate/ gentamicin.....	37
PHENERGAN / CODEINE.....	25	Prednisolone Syrup.....	15
PHENERGAN DM.....	25	Prednisone.....	15
PHENERGAN VC.....	25	PRELONE.....	15
PHENERGAN VC & COD.....	25	PREMARIN.....	15
PHENOBARBITAL.....	7	PREMPHASE.....	16
Phenylephrine.....	38	PREMPRO.....	16
Phenylephrine/ promethazine.....	25	Prenatal vitamins.....	34
PHENYTEK.....	7	PRENATE 90.....	34
PHISOHEX.....	42	PREVACID.....	28
PHOSLO.....	42	PRIMAQUINE.....	15
PILOCAR.....	38	Primaquine Phosphate.....	15
Pilocarpine hydrochloride.....	38	PRINCIPEN.....	12
Pimecrolimus.....	41	PRISTIQ.....	7
Pioglitazone.....	17	PROAIR HFA INHALER.....	25
Pioglitazone/Metformin.....	17	PRO-BANTHINE.....	30
Pipobroman.....	6	Probenecid.....	33
Pirbuterol.....	25	Procainamide.....	20
Piroxicam.....	32	Procainamide SR.....	20
PLAQUENIL.....	33	PROCANBID.....	20
PLAVIX.....	36	Procarbazine.....	6
Podoflox.....	41	PROCARDIA.....	20
POLY PRED SUSP.....	37	Prochlorperazine.....	28
Polyethylene Glycol.....	29	PROCRIT.....	5
Polymyxin/TMP.....	37	PROCTOCREAM HC.....	41
Polysporin ointment.....	39	PROFILNINE.....	5
POLYTRIM.....	37	PROGRAF.....	6
POLY-VI-FLOR.....	34	PROLIXIN.....	7
POLY-VI-FLOR w/ iron.....	35	Promethazine.....	28
Polyvinyl Alcohol.....	38	PRONESTYL.....	20
POLY-VI-SOL.....	34	Propanthelene.....	30
POLY-VI-SOL w/iron.....	35	PROPINE.....	38
Posaconazole.....	14	PROPLEX.....	5
Potassium Cl efferv Tabs.....	35	Propranolol.....	20
Potassium Cl Liquid.....	35	Propranolol ER.....	20
Potassium Cl tab.....	35	Propylthiouracil.....	18
PRAVACHOL.....	23	PROSOM.....	7
Pravastatin.....	23	PROTONIX.....	28
Prazosin.....	22		
PRECOSE.....	17		

PROTOPIC.....	41
PROVENTIL	25
PROVERA	16
PROVIGIL.....	7
PROZAC, WEEKLY	7
Pseudoephedrine	24
PSORCON, -E.....	41
Psyllium powder	29
PTU.....	18
PULMICORT RESPULES	26
PULMOZYME	5
PURINETHOL.....	6
Pyrazinamide	14
PYRAZINAMIDE	14
Pyrethins combo.....	41
PYRIDIDIUM	30
Pyridostigmine.....	34
Pyridoxine	14
Pyrimethamine	15

Q

QUESTRAN.....	23
QUESTRAN LIGHT.....	23
QUINAGLUTE	20
Quinapril.....	21
Quinapril/HCTZ.....	21
QUINIDEX	20
Quinidine gluconate.....	20
Quinidine Sulfate.....	20
QUINIDINE SULFATE	20
Quinidine sulfate SR.....	20
QVAR.....	26

R

Raloxifene.....	18
RANEXA	19
Ranitidine.....	28
Ranitidine bismuth citrate	28
Ranolazine.....	19
RAPAMUNE	6
RAPTIVA	5
RAZADYNE.....	30
REBETOL	5
REBETRON.....	5
RECOMBINATE.....	5
REFACTO.....	5
REFERON.....	5
REGLAN.....	29
RELAFEN	33
RELPAK.....	33

REMERON.....	7
REMODULIN	5
RESCRIPTOR.....	7
RESTORIL.....	7
RETIN A.....	39
RETROVIR.....	7
REVATIO	5
REVLIMID	5
REYATAZ.....	7
RHEUMATREX	6
RHOGAM	5
RIBAVIRIN.....	5
RIFADIN	14
Rifampin.....	14
RISPERDAL	7
RITALIN, SR, LA.....	7
Rivastigmine.....	30
ROBAXIN.....	34
ROBITUSSIN.....	25
ROBITUSSIN AC.....	25
ROBITUSSIN DAC.....	25
ROBITUSSIN DM.....	25
ROCALTROL	35
Rosuvastatin	23
ROZEREM	7

S

SAIZEN.....	5
Salmeterol.....	25
Salsalate	31
SANDIMUNNE	6
SANDOSTATIN	5
SARAFEM	7
Saxagliptin	17
Saxagliptin/Metformin	17
Scopolamine.....	38
SECONAL SODIUM.....	7
Selegiline.....	34
Selenium Sulfide	42
SELSUN SHAMPOO- Rx	42
SEPTRA	14
SERAX	7
SEREVENT.....	25
SEROQUEL.....	7
SERZONE.....	7
SILVADENE	39
Silver Sulfadiazine	39
Simethicone.....	28
Simvastatin	23
SINEMET	34

SINEQUAN	7
SINGULAIR	26
Sirolimus.....	6
Sitagliptin	17
Sitagliptin/Metformin	17
SLO-BID GYROCAPS.....	26
SLO-NIACIN	23
Smz/tmp	14
Sodium Bicarbonate	28
SODIUM BICARBONATE	
TABS	28
Sodium Chloride	
solution-canister	27
Sodium Fluoride	
drops/tabs	35
Sodium Polystyrene.....	42
SODIUM SULAMYD.....	37
SOMA 350 mg.....	34
SOMA COMPOUND.....	34
SOMNOTE, NOCTEC	7
SONATA	7
Spermicidal Jelly/foam	42
SPIRIVA.....	27
Spiroinolactone	22
Spiroinolactone/HCTZ.....	22
SPRYCEL	5
STAVZOR	7
STELAZINE.....	7
STIMATE.....	5
STRATTERA	7
SUBOXONE.....	7
Sucralfate	28
SUDAFED	24
Sulfacetamide.....	37
Sulfacetamide/prednisolone.....	37
Sulfasalazine	29
Sulfisoxazole.....	14
Sulfisoxazole/ erythromycin Susp.....	14
Sulindac	32
SULTRIN VAG CREAM	30
Sumatriptan	33
SUMYCIN	13
SUPRAX	12
SURMONTIL.....	7
SUSTIVA.....	7
SUTENT	5
SYMBICORT	26
SYMBYAX	7
SYMMETREL	14, 34

SYNAGIS	5
SYNAREL	5, 18
SYNALAR.....	40
SYNTHROID.....	9, 18

T

Tacrolimus.....	6, 41
TAGAMET	28
Tamoxifen.....	6
TAPAZOLE.....	18
TARKA.....	21
TAVIST	24
TEGRETOL, XR.....	7
Telithromycin.....	13
TEMODAR.....	5
TENORETIC.....	19
TENORMIN	20
Terazosin.....	22, 30
Terbinafine tablets.....	14
Terbutaline	25
TESLAC	6
TESSALON PERLES.....	25
Testolactone.....	6
Tetracycline	13
TEVTROPIN	5
THALOMID.....	5
THEO-DUR.....	26
Theophyllines.....	26
THERA-M.....	35
THERAPEUTIC TAB	35
THIOGUANINE	6
THORAZINE	7
Thyroid desiccated	18
THROMATE	5
THYROGEN	5
TIAZAC	20
TICLID	36
Ticlopidine	36
TIGAN.....	28
Timolol maleate	37
TIMOPTIC SOLUTION	37
TIMOPTIC-XE GEL.....	37
TINACTIN	40
Tiotropium Bromide	27
Tizanidine.....	34
TOBI	5
TOBRA-DEX.....	37
Tobramycin	37
Tobramycin /dexamethsone.....	37
TOBEX.....	37

TOFRANIL, PM.....	7
Tolazamide	17
Tolbutamide	17
TOLINASE	17
Tolnaftate cream.....	40
Tolterodine Tartrate ER.....	30
TOPAMAX	7
TOPICORT	41
TOPICORT LP.....	40
TOPROL XL.....	20
TORADOL	33
Toremifine	6
TRACLEER.....	5
Tramadol HCL	31
Trandolapril.....	21
Trandolapril / Verapamil ER	21
TRANXENE T-TAB.....	7
TRAVATAN Z.....	38
TRELSTAR	5
TRENTAL	23
Tretinoin	6, 39
Triamcinolone acetonide.....	40
Triamcinolone/ nystatin	40
Triamterene/HCTZ.....	22
TRIAVIL, ETRAFON	7
TRIDESILON.....	40
Trifluridine	37
TRILEPTAL.....	7
TRILAFON.....	7
Trimethobenzamide	28
Trimethoprim	15
TRIMOX.....	12
TRIMPEX.....	15
TRIPHASIL	16
Triple Antibiotic ointment	39
Triple sulfa vag cream.....	30
Tripolidine/ Pseudoephedrine.....	24
TRITEC	28
TRI-VI-FLOR.....	35
TRIZIVIR	7
Tropicamide	38
TRUE TRACK/ TRUE~RESULT	17
TRUE TRACK/ TRUE TEST	17
TRUSOPT	37
TRUVADA.....	7
TUMS	28, 35
TUSSI-ORGANIDIN NR.....	25

TUSSI-ORGANIDIN- DM NR	25
TYKERB	5
TYLENOL	31
TYLENOL W/ CODEINE	32
TYLOX.....	32

U

ULTRAM	31
ULTRAVATE.....	40
UNIPHYL.....	26
URECHOLINE	30
UROXATROL.....	30

V

VALISONE	40
VALIUM	7
VANDAZOLE.....	30
VANTAS	5
Varenicline.....	31
VASOCIDIN.....	37
VASOCON-A.....	36
VASORETIC.....	21
VASOTEC.....	21
VEETIDS	12
VEPESID	6
Verapamil	20
Verapamil SR.....	20
VERCYTE.....	6
VERMOX	15
VESANOID	6
VIBRAMYCIN	13
VICODIN	32
VICODIN ES.....	32
VIDAZA.....	5
VIDEX, EC	7
VIMPAT	7
VIRACEPT	7
VIRAMUNE.....	7
VIREAD	7
VIROPTIC.....	37
VISTARIL	23
VISUDYNE.....	5
VITAMIN B-6	14
Vitamin D.....	34
Vitamin K.....	34
VIVACTIL	7
VIVELLE	16
VOLTAREN	32, 36
VOSOL	38

VOSOL HC OTIC.....	39	ZARONTIN	7
VYTORIN.....	23	ZAROXOLYN.....	22
VYVANSE.....	7	ZEBETA	20
W		ZERIT	7
Warfarin.....	9, 35	ZESTORETIC	21
WELLBUTRIN, SR, XL	7	ZESTRIL.....	21
WESTCORT	40	ZIAC	20
WHINRHO	5	ZIAGEN.....	7
WYGESIC.....	31	ZITHROMAX	13
X		ZITHROMAX 1GM POWDER PACK.....	13
XALATAN.....	38	ZOCOR	23
XANAX, XR.....	7	ZOFRAN	28
XELODA.....	5	ZOLADEX	5
XOLAIR	5	Zolmitriptan.....	33
XYLOCAINE.....	42	ZOLOFT	7
XYLOCAINE VISCOUS.....	39	ZOMIG.....	33
Y		ZONEGRAN	7
YASMIN	16	ZOVIRAX.....	14, 42
Z		ZYBAN	31
ZADITOR OTC	36	ZYLOPRIM	33
Zafirlukast	26	ZYMAR	37
ZANAFLEX	34	ZYPREXA, ZYDIS	7
ZANTAC.....	28	ZYRTEC OTC	24
		ZYRTEC SYRUP OTC.....	24
		ZYRTEC-D OTC.....	24



100 W. Big Beaver Rd., Suite 600
Troy, MI 48084
www.MolinaHealthcare.com

RX Prior Authorizations
Rx Phone Hotline
888-898-7969

Fax Hotline
888-373-3059

Please refer to the Molina website for the
most up-to-date Drug Formulary.